Corrected on Aug 12, 2022.

Source: the publisher, via Crossref · checked Oct 16, 2026 · Read the notice

Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions

Chuan Qin, Sheng Yang, Yun-Hui Chu and 7 more

Signal Transduction and Targeted Therapy · 2022 · Review · CC BY

Abstract

Ischemic stroke is caused primarily by an interruption in cerebral blood flow, which induces severe neural injuries, and is one of the leading causes of death and disability worldwide. Thus, it is of great necessity to further detailly elucidate the mechanisms of ischemic stroke and find out new therapies against the disease. In recent years, efforts have been made to understand the pathophysiology of ischemic stroke, including cellular excitotoxicity, oxidative stress, cell death processes, and neuroinflammation. In the meantime, a plethora of signaling pathways, either detrimental or neuroprotective, are also highly involved in the forementioned pathophysiology. These pathways are closely intertwined and form a complex signaling network. Also, these signaling pathways reveal therapeutic potential, as targeting these signaling pathways could possibly serve as therapeutic approaches against ischemic stroke. In this review, we describe the signaling pathways involved in ischemic stroke and categorize them based on the pathophysiological processes they participate in. Therapeutic approaches targeting these signaling pathways, which are associated with the pathophysiology mentioned above, are also discussed. Meanwhile, clinical trials regarding ischemic stroke, which potentially target the pathophysiology and the signaling pathways involved, are summarized in details. Conclusively, this review elucidated potential molecular mechanisms and related signaling pathways underlying ischemic stroke, and summarize the therapeutic approaches targeted various pathophysiology, with particular reference to clinical trials and future prospects for treating ischemic stroke.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 16, 2026. Paragraph numbers are ours, so an answer can point at one.

Epidemiology, diagnosis, and treatment for ischemic stroke

1Ischemic stroke is caused by an interruption in cerebral blood flow, induced by thrombosis or embolism. It represents the second leading cause of deaths worldwide, with 5.9 million deaths and 102 million disability-adjusted life years lost., Several risk factors have been implicated in the pathogenesis of ischemic stroke, including diabetes, cigarette smoking, hyperlipidemia, and hypertension. Based on the etiology, the cause of ischemic stroke can be traced to embolism from the heart, artery-to-artery embolism, and in situ small vessel disease., Typically, stroke symptoms include sudden unilateral weakness, numbness, diplopia, slurred speech, ataxia, and non-orthostatic vertigo. Various efforts have been made to improve outcome after stroke onset. Immediate clinical interventions, such as intravenous thrombolytic treatment and mechanical thrombectomy, contribute to the recanalization of cerebral blood vessels. While antithrombotic therapies, including antiplatelet or anticoagulant agents, are recommended for nearly all patients with no contraindication, pharmacological approaches against ischemic stroke remain limited, suggesting the need for new treatments.

Morphological changes in ischemic stroke

2In the pathogenesis of ischemic stroke, various types of cells in the central nervous system experience different morphological alterations facing ischemic damages. In the ischemic core, neurons undergo morphological changes where the cell bodies and axons disappear., Swelling of the cytoplasm and nucleolus disappearance are often seen in neurons as well as glial cells. While in the penumbra, neurons, which are referred to as ‘ischemic neurons’ and relatively viable, usually experience several changes such as endoplasmic ribosomes and Nissl bodies disintegration. Besides neurons, glial cells, including microglia and astrocytes, also experience morphological changes after ischemia. Ramified microglia can transform into an “activated state”, characterized by swollen ameboid-like cells, accompanied by the production of pro-inflammatory substances, including cytokines, chemokines, and reactive oxygen species (ROS), while astrocytes usually undergo gradual alterations both in molecular expression profiles and morphologies, which serves to protect neurons in the ischemic penumbra., After ischemia, increased blood-brain barrier (BBB) permeability contributes to the infiltration of several immune cells including leukocytes, monocytes, and macrophages, into the ischemic lesions, which release a variety of neurotoxic or neurotrophic factors to exert either neuroprotective or detrimental effects on ischemic brain tissues.–

3The temporal and spatial alterations in ischemic stroke are illustrated in Fig. 1.

Experimental models of ischemic stroke

4Efforts have been made to elucidate the pathophysiological mechanisms and screen potential therapeutical targets of ischemic stroke, and models both in vivo and in vitro are utilized to mimic ischemic circumstances. The most frequently used experimental ischemic stroke model is middle cerebral artery occlusion model (MCAO), in which a filament is utilized to block cerebral blood flow from the middle cerebral artery to induce a transient occlusion., This model was mostly used for studying blood-brain barrier disruption and inflammatory response in cerebral ischemia., Besides MCAO model, photothrombosis model is also utilized to induce cerebral ischemia in both mice and rats. In this model, Rose Bengal, a photosensitive dye is injected systematically into the animal, while a 532 nm wavelength laser is directly illuminated onto the skull and react with the photosensitive dye. Advantage of this model include the possibility to select a specific cortical brain region for ischemia and the high reproducibility with very low mortality. Correspondingly, the most frequently used in vitro model to mimic ischemic stroke is the oxygen and glucose deprivation (OGD) model, in which oxygen is replaced by N2 and glucose in the medium is omitted. Often this model is combined with cell co-cultures to study cellular interactions under ischemic circumstances. However, a limitation still remains that the in vitro model should be combined with in vivo studies to better comprehensively understand ischemic stroke.

Pathophysiological mechanisms involved in ischemic stroke

5As a hallmark of ischemic stroke, interrupted cerebral blood flow depletes the brain of oxygen and glucose, which leads to disrupted ATP synthesis and energy deficiency, as well as impaired ion homeostasis and acid-base imbalance., All these dysfunctions result in cerebral neuropathological changes, such as brain edema, neuroinflammation, and neural cell death, eventually underpinning severe neurological deficits. Progress has been made in unveiling the pathogenesis and mechanisms of stroke, including cellular excitotoxicity, mitochondrial dysfunctions, neuroinflammation, BBB impairment, and cell death processes. Various signaling pathways become activated in these pathological transitions, and their targeted regulation could serve as a potential therapeutic strategy. Given the complex pathophysiology of ischemic stroke, the accompanying injury and signaling mechanisms should be first identified and then further elucidated to develop targeted interventions.

6The present review describes various signaling pathways associated with ischemic stroke pathophysiology (Fig. 2) and categorizes the corresponding therapeutic approaches (Table 1). Additionally, we summarize evidence from national clinical trials assessing therapies targeting ischemic stroke (Table 2).

Energy deficiency due to a lack of glucose and oxygen

7Immediately after ischemic stroke, cerebral blood flow is significantly reduced, which limits the availability of glucose and oxygen, especially in neurons. Energy disruption leads to mitochondrial dysfunction and oxidative stress-induced damage, triggered by the production of ROS. Concurrently, energy deficiency contributes to an ionic imbalance that affects Na+, K+, and Ca2+ levels, leading to cell depolarization and prompting glutamate release. The excessive glutamate activates N-methyl-D-aspartate receptors (NMDARs), inducing toxicity, cell death, and finally severe damage of the central nervous system.– Taken together, deficiency in glucose and oxygen may eventually lead to cellular excitotoxicity and mitochondrial dysfunctions, which serve as the initiating session of ischemia-induced damage and subsequently cause other cascade of injuries. In this section, the review focuses on the various signaling pathways involved in glutamate and NMDAR-induced cell toxicity, namely, excitotoxicity, as well as oxidative stress and mitochondrial dysfunction in ischemic stroke.

Excitotoxicity and related signaling pathways

8Glucose and oxygen deficiency during cerebral ischemia induces neuronal cell depolarization and glutamate release. The latter then stimulates Na+/Ca2+ channels coupled with NMDARs. Enhanced Ca2+ influx perturbs ionic homeostasis, resulting in Ca2+ overload in both the mitochondria– and cytosol. These changes stimulate a variety of proteases, lipases, kinases, phosphatases, endonucleases, and free radicals,, as well as biological processes causing cell death, such as calpain activation, oxidative stress, and mitochondrial impairment., Overall, these cellular dysfunctions are termed excitotoxicity and involve NMDARs, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, and kainite receptors.,

9Despite their involvement in ischemic stroke-related excitotoxicity, NMDARs act as a double-edged sword. Functional and structural studies have revealed that activation of NMDARs containing the GluN2B subunit triggers excitotoxicity during ischemic stroke and subsequent neuronal apoptosis, whereas activation of NMDARs containing the GluN2A subunit exerts a neuroprotective effect., Similarly, it has been hypothesized that synaptic NMDARs promote neuronal survival, whereas extra-synaptic NMDARs play detrimental roles in neuronal activity. The analogy between synaptic vs. extra-synaptic NMDARs and GluN2A-containing NMDARs vs. GluN2B-containing NMDARs demonstrates the dual effect of NMDARs and their regulation of signaling pathways with neuroprotective or detrimental effects on ischemic stroke (Fig. 3).

Phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway

10Stimulation of synaptic NMDARs activates the pro-survival PI3K/Akt signaling pathway, thereby exerting a neuroprotective effect. PI3K is an intracellular kinase classified into three categories (I, II, and III) based on structure and substrate specificity. In neurons, activation of the PI3K/Akt signaling pathway by NMDAR occurs via Ca2+ and calmodulin, which recruit phosphoinositide-dependent protein kinase 1. At the same time, Ca2+ triggers tyrosine phosphorylation of insulin receptor substrate 1, reinforcing NMDAR-induced Akt activation.– The protective effect of the PI3K/Akt signaling pathway on ischemic stroke has been reported both in in vitro neurons during hypoxia– and in vivo against ischemic neuronal death,,–, and PI3K/Akt signaling inhibition aggravates ischemia-induced neuronal death in experimental stroke animals.,,, Mechanistically, the neuroprotective effect of Akt is related to the phosphorylation and inactivation of various downstream targets, including glycogen synthase kinase 3 beta (GSK3β), pro-apoptotic B-cell lymphoma 2 (Bcl2)-associated BAD, c-Jun N-terminal kinase (JNK)/p38 activator ASK1, and apoptotic p53. These effects not only exist in neurons, but also in other neural cell types, which are possibly related to the inhibition of synaptic excitotoxicity and thus exert neuroprotective effects in ischemic stroke.

Brain-derived neurotrophic factor (BDNF) and cAMP-response element-binding protein (CREB)-related gene products

11Synaptic NMDAR activation and Ca2+ influx activate the Ras/extracellular signal-regulated kinase (ERK) signaling pathway and nuclear Ca2+/calmodulin-dependent protein kinases, which in turn phosphorylate and activate CREB., Together with NMDAR and BDNF, CREB promotes the expression of numerous pro-neuronal survival genes.– BDNF production in the brain relies on Ca2+ influx through NMDAR.,, Synaptic NMDARs promote BDNF gene expression, whereas extra-synaptic NMDARs block CREB-mediated BDNF expression. In experimental ischemic stroke models, BDNF is secreted into the brain and protects against ischemia-induced injury via neuronal GluN2A-NMDAR activation., Together, these results show that BDNF and, to some extent, the upstream CREB signaling pathway contribute to the neuroprotective effect associated with synaptic excitotoxicity in cerebral ischemia.

Phosphatase and tensin homolog (PTEN) signaling pathway

12Extra-synaptic NMDARs are closely linked to signaling pathways associated with cell death and often contradict the effects triggered by synaptic NMDARs. Upon activation by Ca2+ influx through NMDARs, PTEN is recruited to GluN2B-NMDARs. The direct interaction between PTEN and the GluN1 subunit of GluN2B-NMDARs enhances current flow through the channel, tightening the junctions between PTEN and the neuronal death signaling complex. Concurrently, the excitotoxic stimulation of NMDARs initiates PTEN nuclear translocation, thus significantly lowering the phosphorylation of phosphatidylinositol-trisphosphate and Akt and consequently blocking PI3K/Akt signaling., Thus, contrary to the protective effect of PI3K/Akt, PTEN signaling may decrease cell survival and induce neuronal death. In agreement with this hypothesis, downregulating PTEN expression reportedly inhibits extra-synaptic NMDAR currents and protects neurons from experimental ischemic injury. The above evidence hints at the detrimental role of PTEN in ischemic stroke, which is largely mediated by regulation of extra-synaptic NMDAR activities.

Death-associated protein kinase 1 (DAPK1) signaling pathway

13DAPK1 is a Ca2+/calmodulin-dependent serine/threonine-protein kinase, whose phosphorylation contributes to apoptotic cell death., DAPK1 participates in excitotoxicity in ischemic stroke. During ischemia, NMDAR overactivation promotes Ca2+ influx, activates Ca2+/calmodulin, and stimulates calcineurin phosphatase, which subsequently dephosphorylates and activates DAPK1. The latter is then transferred to the GluN2B subunit of NMDARs, aggravating ischemic injury. Preventing the interaction between GluN2B and DAPK1 attenuated neuronal excitotoxicity in mouse ischemic stroke models and downregulated the NMDAR current in vitro. In addition, NMDAR-regulated calcineurin activation contributes to DAPK1 activation, whereas NMDAR or calcineurin inhibition prevents DAPK1 dephosphorylation. DAPK1 inhibition protects against ischemic injury both in cultured neurons and in vivo, suggesting that potential treatments for ischemic stroke could be based on inhibiting DAPK1. It is interesting to note that the pro-survival signaling factor ERK serves as a downstream effector of DAPK1, and the DAPK1-ERK interaction could block the neuroprotective effect of ERK on experimental ischemic stroke, possibly by retaining ERK in neuronal cytoplasm.

Postsynaptic density protein-95 (PSD95)/neuronal nitric oxide synthase (nNOS) signaling pathways and excitotoxicity-induced cell death

14Neuronal NMDARs contribute to nitric oxide production, which is associated with calcium/calmodulin and is regulated by nNOS. NMDAR subunits bind directly to PSD95, which is composed of three PDZ domains.– The binding of PSD95 to NMDAR and nNOS enhances Ca2+ influx, a hallmark of excitotoxicity., PSD95/nNOS signaling may play a pivotal role in ischemic stroke, as evidenced by the amelioration of neurological deficits in animals suffering from cerebral ischemia and whose nNOS activity was inhibited by either pharmacological or genetic means. Cerebral ischemia has been shown to enhance NMDAR/PSD95/nNOS interactions in neurons, thus further aggravating brain injuries after experimental ischemic stroke. All these results show that signaling through the PSD95/nNOS complex is crucial for excitotoxicity in ischemic stroke and contributes to the neurotoxic effects of extra-synaptic NMDARs.

Mitochondrial dysfunction, oxidative stress, and related signaling pathways

15Mitochondria are essential for maintaining energy homeostasis. When ATP synthesis and energy balance are disrupted by a lack of glucose and oxygen, the status and function of mitochondria become substantially altered. Ca2+ influx leads to mitochondrial permeability transition pore (MPTP) opening and cytochrome c release., At the same time, insufficient ATP supply triggers mitochondrial membrane depolarization, which is characterized by the influx of Na+ and efflux of K+.– Besides mitochondrial dysfunction, energy deficiency in cerebral ischemia leads to oxidative stress, which severely damages cells and brain tissues. Oxidative stress accompanies several pathological processes and results from increased ROS production, mostly via oxidative phosphorylation in the mitochondria. Considering the intimate link between ROS and mitochondrial metabolism, mitochondrial dysfunction is often related to oxidative stress pathologies. During ischemia, oxidative damage and excessive Ca2+ levels contribute to MPTP induction, which further promotes succinate release and mitochondrial damage-associated molecular patterns including the activation of downstream inflammatory responses.– Consequently, all these damaging factors lead to neurotoxic and cell death processes, in which a plethora of signaling pathways are involved (Fig. 4).

Hypoxia-inducible factor (HIF) signaling pathway

16HIF-1, a key transcription factor activated during cerebral ischemia and hypoxia, comprises two subunits: HIF-1α and HIF-1β.– HIF-1 enhances the expression of several glycolysis-associated genes under hypoxic conditions, thus helping cells and tissues become accustomed to hypoxia. Also, HIF-1α expression strongly correlates with ROS levels, with HIF-1α chains stabilized by the large quantities of ROS generated under hypoxia., In a positive feedback loop, lack of oxygen and glucose due to ischemia may enhance HIF-1 expression, thereby causing oxidative stress and further stimulating HIF-1 activity.

17Conversely, it has been reported by other studies that HIF-1α may also play protective roles in the regulation of energy metabolism, especially in neurons. Consequently, HIF-1α depletion in mouse embryo fibroblasts results in excessive ROS, reduced glycolytic metabolism, and cell death. Besides controlling ROS production, the activation of HIF-1α may benefit cellular homeostasis by maintaining the redox equilibrium. Knockout of HIF-1α has been shown to disrupt redox homeostasis and glucose metabolism, such as pentose phosphate pathway and glucose transportation in SHSY5Y cell lines cultured under oxygen-glucose deprivation. In summary, HIF signaling may be closely associated with oxidative stress. Although there is still debate whether HIF-1α signaling enhances oxidative stress or not, activation of HIF-1α may be closely associated with production of ROS and oxidative stress, which consequently affects cellular redox equilibrium and biological activities.

Nuclear factor E2-related factor 2 (Nrf2) signaling pathway

18Nrf2 regulates cellular redox homeostasis and counteracts oxidative stress. Nrf2 activation protects individuals against cerebral ischemic damage. In the resting state, Nrf2 is coupled to Keap1, its specific cytoplasmic receptor. The structure of Keap1 changes upon electrophilic or oxidative stress. As Nrf2 is phosphorylated through the protein kinase C pathway, it becomes uncoupled from Keap1, leading to enhanced expression of various anti-inflammatory proteins, antioxidant enzymes, and growth factors., In ischemic stroke, oxidative stress caused by elevated ROS levels induces Nrf2 accumulation in the nucleus, where it binds to antioxidant response elements (ARE) and maintains normal mitochondrial function. In contrast, insufficient Nrf2 contributes to neuronal mitochondrial depolarization, ATP depletion, and respiratory function impairment. suggested the beneficial role of Nrf2 in mitochondria.

19A variety of downstream signaling pathways, including PI3K/Akt, ERK/mitogen-activated protein kinase (MAPK), and nuclear factor kappa beta (NF-κB), potentially mediate the antioxidant effect of Nrf2 during ischemia. The neuroprotective PI3K/Akt pathway induces the nuclear translocation of Nrf2, which in turn stimulates the production of various antioxidants., Likewise, ERK/MAPK signaling pathway during ischemia is associated with a variety of neuroprotective biological processes, such as preventing apoptosis or enhancing Nrf2 phosphorylation and translocation., Also, NRF2 and NF-κB signaling pathways closely interact with each other under a variety of circumstances. On the one hand, deletion of NRF2 results in increased inflammation, as well as high levels of NF-κB; on the other hand, the elevated expression of NRF2 inhibits NF-κB-regulated pro-inflammatory and immune responses. This show the neuroprotective effects of NRF2 against NF-kB-induced inflammatory responses in cerebral ischemia.

20In summary, Nrf2 is a crucial player against oxidative stress and mitochondrial dysfunction in ischemic brain injuries, possibly via the regulation of various downstream signaling pathways.

Casein kinase 2 (CK2) signaling pathway

21CK2, an important oncogenic kinase, is crucial for counteracting ROS accumulation. First, it exerts a protective effect by inhibiting NADPH oxidase via regulating Rac1, a GTPase which significantly activate NADPH oxidase, possibly through interactions with other subunits and link the cytosolic subunits with the cell membrane.– Second, CK2 reportedly phosphorylates Janus kinase and signal transducer and activator of transcription 3 (STAT3), enabling ROS detoxification by superoxide dismutase 2 (SOD2)., Third, CK2 activates HIF-1α and phosphorylates NF-κB to promote the release of vascular endothelial growth factor (VEGF) and angiogenic proteins under in vitro hypoxic conditions., Conversely, CK2 inhibition in the ischemic region contributes to poly (ADP-ribose) polymerase 1 accumulation, which leads to the release of mitochondrial cytochrome c and apoptosis-inducing factor (AIF), with subsequent activation of downstream apoptotic events. These findings reveal the protective effect of CK2 against oxidative stress and inflammation, while promoting the release of angiogenic factors under hypoxia.

22Notably, CK2 was shown to activate ROS-generating NADPH oxidase isoform 2 in an experimental ischemic stroke model, which induced AIF release into the mitochondria and subsequent DNA damage and apoptosis. Moreover, studies have shown that cyclin dependent kinase 5 and AKT/GSK3β are activated by CK2 in ischemia/reperfusion injuries. Given that inhibition of cyclin dependent kinase 5 reportedly alleviates cerebral ischemic stroke-induced damage, CK2 may do more harm than good., Taken together, the CK2 signaling pathway and related molecules play either protective or detrimental roles in ischemic stroke, especially in relation to oxidative stress. Importantly, downstream effectors of CK2 may function as potential targets against ischemic stroke.

Mitophagy and related signaling pathways

23Mitophagy describes the process whereby mitochondrial content is taken up by mitochondria-derived vesicles and then transferred to lysosomes or peroxisomes for degradation. Mitophagy is essential for maintaining cellular homeostasis and serves as a protective strategy in various central nervous system diseases. Signaling pathways, such as PTEN induced kinase 1 (PINK1)/Parkin, Bcl2-interacting protein 3 (Bnip3), BNIP3-like, and FUN14 domain containing 1 pathways, are reportedly involved in mitophagy during ischemia–reperfusion. In the reperfusion stage, the levels of the free radical ONOO− are increased, which leads to dynamin related protein 1 recruitment to the mitochondria and PINK1/Parkin-associated mitophagy. Meanwhile, elevated ROS levels upregulate the levels of Parkin RBR E3 ubiquitin protein ligase, which is recruited by PINK1, further exacerbating mitophagy. Interestingly, PINK1-regulated mitophagy is mechanistically associated with MPTP opening, whereas Bnip3-induced mitophagy is independent of MPTP.,

24The activated mitophagy pathway may alleviate oxidative stress-induced cell injuries by promoting the degradation of damaged mitochondria. Enhanced mitophagy has been shown to possibly ameliorate ROS accumulation in cerebral ischemic stroke. In conclusion, mitophagy is significantly involved in the pathophysiology of ischemic stroke, along with the activation of various signaling pathways. Targeting these signals could potentially ameliorate the pathological changes and symptoms of ischemic stroke; however, the mechanisms remain to be elucidated.

Cell death signaling pathways in ischemic stroke

25Damage caused by excitotoxicity, oxidative stress, and mitochondrial dysfunctions in ischemic stroke may induce a variety of cellular signaling cascades, which lead neural cells to undergo either programmed or unprogrammed death. Usually, programmed cell death includes apoptosis and autophagy, which are normal cellular functions, whereas unprogrammed cell death involves necrosis and is likely caused by external stimuli. Lack of oxygen and glucose in the ischemic core often leads to irreversible necrosis; in contrast, relatively minor damage in the penumbra is responsible for reversible death processes, such as apoptosis and autophagy. A variety of signaling pathways are highly involved in cell death, and they could either enhance or inhibit the process (Fig. 5).

Signaling pathways related to autophagy in stroke

26Autophagy is a self-protective pathway that maintains cell homeostasis and promotes cell survival by degrading circulating long-lived proteins, misfolded and aggregated proteins, and damaged organelles to obtain energy or in response to cellular stress. Subsequently, autolysosomes are newly formed to cleave the cargo for subsequent recycling. Emerging evidence indicates that autophagy is activated in various cell types following ischemic stroke, including neurons, glial cells, and endothelial cells. Autophagy can exert either beneficial or detrimental effects on cerebral ischemic injuries, as moderate autophagy may help degrade aggregated proteins,– whereas inadequate or excessive autophagy may eventually lead to cell death. The dual role of autophagy in ischemic stroke may be explained by the involvement of multiple signaling pathways, such as mammalian target of rapamycin (mTOR), 5′-AMP-activated protein kinase (AMPK), MAPK, NF-κB, p53, HIF-1, and Bcl2 pathways.

mTOR-related signaling pathways

27mTOR is a serine/threonine protein kinase that comes in two major forms: mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin-insensitive). The former is responsible for cell growth and cell cycle progression, whereas the latter contributes to cellular skeleton formation. mTOR is a key regulator of the initial phase of autophagy, as it senses changes in signaling within the cell. Usually, mTOR limits autophagy by inhibiting phosphorylation of the Atg1/ULK1 protease complex. During ischemic stroke, mTOR interacts with multiple signaling pathway components that regulate autophagy, including PI3K/Akt, AMPK, and MAPK.

28Akt, which is involved in various biological processes, can affect cellular autophagy through multiple signaling pathways, of which PI3K/Akt/mTOR is the most important one.– The PI3K/Akt signaling pathway was suggested to exert a neuroprotective effect on ischemic stroke, possibly by regulating mTORC and, hence, autophagy in both mice MCAO models and OGD-treated primary neurons in vitro. Another study found that inhibition of mTOR by rapamycin activated the PI3K/Akt signaling pathway and, in turn, autophagy, thus protecting neonatal rats against hypoxia. Interestingly, homocysteine exerts a neurotoxic effect, possibly owing to excessive autophagy following downregulation of PI3K/Akt/mTOR signaling in neural stem cells, suggesting the bi-faceted role of autophagy in ischemic stroke.

29AMPK is a member of the serine/threonine kinase family and serves as an important endogenous defense factor against cerebral ischemia. During cerebral ischemia or hypoxia, energy deficiency and the consequent elevated AMP/ATP ratio contribute to AMPK phosphorylation, which activates autophagy to enhance energy production. Several studies on animal experimental ischemic stroke models have found that protective autophagy can be induced by regulating the AMPK/mTOR signaling pathway, thereby alleviating cerebral ischemic injury., A variety of downstream and upstream factors contribute to AMPK activity in both in vivo experimental ischemic stroke models and in vitro. Mechanistically, AMPK inhibits mTORC1 activity by phosphorylating and stimulating the TSC1/TSC2 complex during ischemia, thereby promoting autophagy. Furthermore, during ischemic stroke, Ca2+ overload can activate AMPK via calcium/calmodulin-dependent protein kinase beta and thus activate autophagy via the AMPK/mTOR pathway. Meanwhile, cytosolic p53 has been shown to directly inhibit autophagosome formation, whereas activated p53 functions to promote AMPKβ expression and inhibits mTOR expression to promote autophagy. These molecules contribute to the function of AMPK in autophagy in ischemic stroke.

30MAPK is another important regulator of autophagy associated with ischemic stroke. MAPKs act as upstream regulators of mTORC1 and modulate autophagy through the MAPK/mTOR signaling pathway in ischemic stroke. Wang et al. found that autophagy protected against animal experimental cerebral ischemic injury through induction of an Akt-independent MAPK/mTOR signaling pathway, wherein ERK negatively regulated mTORC1. In contrast, Zhang et al. found that ERK negatively controlled autophagy by activating mTOR, which contributed to neuronal survival after experimental ischemic stroke injuries. Furthermore, an in vitro OGD/R study revealed that ERK could modulate autophagy by regulating mTOR in oxygen-glucose deprivation models. Therefore, the MAPK/ERK signaling pathway family could exert either a positive or negative regulation over mTOR in ischemic stroke; however, the exact mechanisms will require further investigation.

Beclin1/Bcl2 signaling pathway

31Beclin1 plays a significant role in the early stage of autophagy. Local cerebral ischemia can upregulate Beclin1 expression and induce autophagy-like cell death, suggesting the involvement of Beclin1/Bcl2 signaling in the regulation of autophagy in ischemic stroke. Qi et al. found that Bcl2 phosphorylation after cerebral ischemia in rats perturbed the Beclin1-Bcl2 complex and triggered distal ischemic conditional autophagy, thereby alleviating mitochondrial damage. Moreover, peroxisome proliferator-activated receptor γ (PPAR-γ) expression increases during experimental cerebral ischemic injury. Activated PPAR-γ inhibits Beclin1-mediated autophagy, possibly by upregulating the expression of Bcl2/BclXL. Thus, either detrimental or neuroprotective factors impact on Beclin1-Bcl2 signal activities, subsequently affecting autophagy in ischemic stroke.

Other autophagy-related pathways

32Several other signaling pathways are also involved in autophagy during ischemic stroke. Under ischemic conditions, the accumulation of misfolded proteins and disruption of Ca2+ homeostasis lead to self-protective events in the unfolded protein response (UPR) pathway. The UPR can promote autophagy by stimulating the PERK/eIF2 and Ire1/TRAF2/JNK pathways. The UPR signaling pathway mediator, activating transcription factor 6, can also affect autophagy in stroke. Rab7, a lysosome-associated small Rab GTPase, regulates autophagy during cerebral ischemia and provides neuroprotection against ischemic brain injury. Specifically, Rab7 enables the fusion of autophagosomes with lysosomes, thus affecting autophagosome maturation, lysosome formation, and maintenance of lysosomal function. However, the actual mechanisms of UPR signaling and that of Rab7 in ischemic stroke require further investigation.

Signaling pathways related to apoptosis in stroke

33Apoptosis is a highly regulated, energy-dependent form of cell death characterized by distinct morphological changes, such as cell shrinkage, cytoplasmic condensation, nuclear membrane breakdown, and apoptotic body formation. Apoptosis, especially neuronal apoptosis, is involved in the pathology of post-ischemic stroke. Cerebral ischemia leads to a decrease in ATP, which causes cellular apoptosis in the ischemic penumbra. Anti-apoptotic signals enable the potential recovery of dysfunctional neurons, while pro-apoptotic signals contribute to neuronal death, thus modulating the balance between pro-apoptotic and anti-apoptotic signals serve as potential therapeutic targets. Stroke triggers two principal apoptotic pathways: the extrinsic (or death receptor) pathway and the intrinsic (or mitochondrial) pathway. Initiated by a variety of both external and internal damaging stimuli, apoptosis eventually triggers a caspase cascade, which leads to the cellular injuries experienced during ischemic stroke.

Apoptosis by the extrinsic/death receptor pathway

34The extrinsic apoptotic pathway is triggered by the combination of ligands, including TNF-α, FasL, and TRAIL, and the corresponding death receptors (TNF-α receptor 1, Fas/CD95/APO1, and TRAIL-R, respectively) on the cell surface. In the event of an ischemic stroke, the receptor recruits the death domain adaptor proteins FADD and TRADD, which form a complex by binding to procaspase-8. This complex induces a variety of downstream damaging processes and eventually leads to activation of caspase-8. Once activated, caspase-8 triggers downstream effector caspases, either directly via proteolytic cleavage or indirectly by cleaving BH3-interacting domain (BID) to its truncated form, which mediates apoptotic cell death via the mitochondria-dependent pathway., Furthermore, during ischemic injury, neurons and glial cells release TNF-α, increasing Fas mRNA and protein levels. These could function as stimuli for the extrinsic apoptotic pathway and ultimately lead to neuronal death.

Apoptosis by the intrinsic/mitochondrial pathway

35The intrinsic pathway, also called the mitochondrial pathway, is a receptor-independent signaling cascade that affects mitochondrial energy metabolism. Apoptotic stimuli, such as excessive Ca2+ accumulation and oxidative stress, mediate mitochondrial cell death., Lack of ATP due to oxygen and glucose deficiency results in cellular depolarization and excessive glutamate release, both of which further enhance Ca2+ influx.– Ca2+ overload triggers calpain activation, which mediates the cleavage of Bcl2-interacting BID into its truncated active form, together with caspase-8 in the death receptor pathway., Truncated BID interacts with pro-apoptotic Bcl2 family members, forming a dimer and causing MPTP opening. These changes trigger the release of various pro-apoptotic factors, including cytochrome c, endonuclease G, and AIF, which ultimately lead to apoptosome formation by binding to apoptotic protease activating factor-1. Upon apoptosome formation, procaspase-9 becomes activated into caspase-9, which triggers downstream effector caspases (caspase-3, caspase-6, and caspase-7) that promote neuronal cell apoptosis.

p53-mediated apoptotic pathway

36Besides the extrinsic and intrinsic apoptotic pathways, another programmed cell death process activated by ischemic stroke depends primarily on p53. The tumor suppressor p53 becomes activated in ischemic areas of the brain, whereby it contributes to neuronal apoptosis. By translocating to the nucleus and binding to its specific DNA site, p53 induces apoptosis in ischemic brain cells. A plethora of detrimental signals could stimulate p53. One is DNA damage, which can activate the apoptotic pathway via p53 phosphorylation. Another is represented by hypoxia and oxidative stress, which can also upregulate p53 protein levels. Concurrently and mechanistically, some upstream cascade proteins, including JNKs, p38, DAPK, ASK1, and Notch may also lead to p53 activation. All these factors stimulate p53 activity and lead to cellular apoptosis in ischemic stroke.

37p53-induced apoptosis involves a variety of downtream genes and molecules, such as the pro-apoptotic genes Bax, Noxa, p53AIP1, and PUMA, all of which act directly on mitochondria to induce apoptosis. Subsequently, p53 leads to the intrinsic apoptotic pathway, releasing pro-apoptotic factors, forming an apoptosome, activating effector caspases, and inducing neuronal apoptosis. In addition, p53 mediates apoptosis by inducing the expression of paternally expressed 3 and blocking cell survival signaling. All these processes contribute to the onset and progress of p53-mediated apoptosis.

Notch signaling pathways in apoptosis

38Notch signaling pathways, the most important component of which is Notch1, plays pivotal roles in a variety of biological processes in the central nervous system. Activation of Notch1, as well as other signaling pathways, including NF-κB, p53, contributes to neuronal death processes. It has been reported that p53 and Pin1 are highly associated with Notch and NICD in ischemic stroke. As an important mediator of apoptosis, p53 is activated by damages such as hypoxia. The combination of Notch with p53 is crucial for neuronal apoptosis during ischemic stroke, which majorly involves stabilization of p53 and transcriptional regulation of p53 and NICD target genes. Besides, Pin1, an isomerase that regulates p53 transactivation, is deemed to be involved in the pathogenesis of ischemic stroke, which is also related with Notch signaling and is responsible for ischemic stroke-induced neuronal death and neurological deficits.

39In the meantime, studies have shown that Notch plays significant roles in modulating NF-κB-related cell death pathways. For instance, γ-secretase inhibitors down-regulate levels of NICD and protect against ischemic stroke damages. This protection effect is possibly via regulating NF-κB-related signals. Meanwhile, γ-secretase inhibitors block Notch signals and alleviates microglial activation. All these reveal the interactions between Notch and NF-kB pathways in both neurons and microglia in cerebral ischemia.

40Besides, it has also been reported that ischemic stroke increases HIF-1α expression levels, which could directly bind with NICD and NF-κB., Inhibition of both γ-secretase/Notch and HIF-1α significantly reduced cell apoptosis, while enhanced expression of NICD and HIF-1α increased NF-kB levels. All these show the close interactions among NICD, p53, HIF-1α and NF-kB, which are highly associated with neuronal death processes, especially neuronal apoptosis in ischemic stroke.

Necrosis or necroptosis in cerebral ischemia

41Following the onset of stroke, cerebral blood flow in the infarct area becomes significantly reduced, which induces necrotic death of resident neurons. Necrosis is an unprogrammed cell death process caused mainly by decreased ATP in ischemia. Recent studies have reported necrosis to be a highly regulated process involving various signaling pathways. The major downstream signaling pathways controlled by TNF-α include receptor-interacting protein kinase (RIPK1 and RIPK3) and mixed lineage kinase domain-like pathways.

42Facing cerebral ischemic damage, a complex containing TRADD, RIPK1, and ubiquitin 3 ligases is recruited by the combination of TNF-α and its TNFR1120 receptor. Complex IIb is subsequently activated in both ischemia and hypoxia, contributing to the phosphorylation and association of RIPK1 and RIPK3.– Within the complex formed by this association, mixed lineage kinase domain-like is further activated by RIPK3, which eventually leads to cell death. Concurrently, a cascade of inflammatory reactions, including secretion of pro-inflammatory cytokines, favors necrosis damage and exacerbates ischemic brain injuries.

Pyroptosis and ferroptosis in ischemic stroke

43Majorly observed in ischemic penumbra, pyroptosis potentially induces pro-inflammatory pathways in ischemic stroke. During the process of pyroptosis, cells get swollen and cellular organelles are released to induce inflammation, in which caspase-1 is activated and form inflammasomes. All these contribute to pyroptotic cell death and secretion of inflammatory factors, such as IL-1β and IL-18.,

44Another less mentioned but important cell death pathway is ferroptosis. Ferroptosis is regulated by peroxidation, which requires sufficient accessible iron. In ischemic brain regions, enhanced cellular excitotoxicity leads to the decrease in activity of GPX4 and reduction in GSH production, which accumulates excessive ferric ion and subsequently induces ferroptotic cell death. Also, damaged blood-brain barrier induces the iron to be transferred into neuronal cells, which further enhances ferroptosis. From another perspective, ferroptosis is also closely associated with oxidative stress, in which signaling pathways such as calcium-related signals, ATF4 and Keap1-Nrf2 signaling pathways play a role. Despite being less frequently discussed, ferroptosis may also be greatly involved in the pathogenesis of ischemic stroke,with a variety of signaling pathways potentially participating in.

Neuroinflammation, BBB disintegration, and related signaling pathways in ischemic stroke

45Inflammation is a key component of ischemic stroke pathologies. Existing in nearly all stages of ischemic stroke, neuroinflammation is initiated by the release of DAMPs from injured or dead cells. These DAMPs, including adenosine, heat shock proteins, high mobility group box 1, and interleukin-33, are subsequently recognized by corresponding immune cells, and then trigger a variety of downstream signaling pathways., During the whole process of inflammation, various immune cells including microglia, macrophages, and T lymphocytes are activated., Also, the production of inflammation-related cytokines are stimulated, as well as interferons or chemokines including monocyte chemoattractant protein-1 (MCP-1). Upregulation of levels of several adhesion molecules assists leukocytes in adhering to vascular surfaces, which facilitates the infiltration of immune cells. An abundance of pro-inflammatory cytokines leads to BBB disintegration via activation of endothelial cells and pericytes,, along with the release of specific markers, such as von Willebrand factor and nerve growth factor., BBB leakage results in cerebral edema, as well as astrocytic aquaporin 4 expression., All these factors, including MCP-1, von Willebrand factor, nerve growth factor, and aquaporin4, could induce immune cell adhesion to the vascular wall and then infiltrate into the central nervous system, consequently contribute to BBB disintegration and cellular edema.

46Several signaling pathways are involved in neuroinflammatory processes and BBB breakdown in ischemic stroke; they are strongly associated with each other and determine the pathophysiology of cerebral ischemia (Fig. 6).

Cytokine- and chemokine-induced signaling pathways in neuroinflammation

47During ischemic stroke, microglia, which represent the main resident immune cells in the brain, are the first cells recruited to infarct lesions. They secrete both pro-inflammatory cytokines, such as interleukin (IL)-1β, IL-6, and tumor necrosis factor alpha (TNF-α), and anti-inflammatory cytokines, including IL-1R antagonist (IL-1Ra) and IL-10.,– Together, these cytokines form a complex signaling network in ischemic stroke-induced neuroinflammation.

Cytokines

48TNF is the most studied cytokine in ischemic stroke; it comprises a secreted form (solTNF) and a transmembrane form (tmTNF). The signal from both types of TNF is transferred via two different receptors, TNFR1 and TNFR2, respectively. The solTNF-TNFR1 signal is deemed responsible for pro-inflammatory effects of TNF, which trigger cell death signaling pathways. Instead, TNFR2 promotes cell growth and regeneration.,, Given the important regulatory role of TNF signals in inflammation and other neurological processes, TNFs are likely involved in the pathophysiology of ischemic stroke. Genome-wide association studies have identified a polymorphism in the TNF gene, which enhances stroke susceptibility, suggesting a pivotal role of TNF/TNFR1 in the etiopathogenesis of stroke. Moreover, TNF levels are significantly upregulated upon cerebral ischemia, whereby they mediate neuronal plasticity. As previously mentioned, TNF is secreted mainly by microglia, which protect against cerebral ischemia. Specific myeloid cell-TNF-knockout mice have been found to have larger infarct volumes and more severe neurological deficits than control mice., Removal of solTNF in mice reportedly alleviates the symptoms and pathology of cerebral ischemia, suggesting that elimination of solTNF and retention of tmTNF ameliorate cerebral ischemic injuries. Thus, different forms of TNF impact ischemic stroke, corroborating the important role of TNF in this disease.

49The IL-1 family constitutes a huge and complex network of pleiotropic pro-inflammatory cytokines closely involved in regulating immune cells and inflammatory processes. Among IL-1 family members, IL-1α, IL-1β, and IL-1Rα have been studied in detail in relation to ischemic stroke. A polymorphism in the IL-1A gene has been associated with increased susceptibility to stroke; conversely, a polymorphism in the IL-1B gene lowers stroke risk. IL-1α expression is significantly increased in cerebral ischemia. Platelet-derived IL-1α contributes to neurovascular inflammation and causes the infiltration of neutrophils to ischemic lesions. Primarily secreted by microglia and macrophages,, IL-1β affects neurons, glial cells, and the vasculature. IL-1β levels are significantly increased in the cerebrospinal fluid at days 2 and 3 post-stroke, suggesting a predictive value in stroke pathophysiology., The IL-1 family has been shown to exacerbate stroke pathology, as revealed by reduced infarct volumes in experimental ischemic stroke models of IL-1α/β knockout mice. Conversely, IL-1β administration worsens the outcomes of mice subjected to ischemic stroke. Overall, the IL-1 family plays a detrimental role in the pathophysiology of cerebral ischemic stroke and could serve as a potential therapeutic target.

50Another vital member among pro-inflammatory interleukins is IL-6, which is secreted by a variety of cells, including monocytes, neurons, and glial cells., The IL-6 signaling pathways can be classified into classic signaling, which requires IL-6R and gp130, and trans-signaling, whereby IL-6 is linked to sIL-6R. Reportedly, the former is deemed to be neuroprotective and helps maintain neuronal homeostasis, whereas the latter contributes to IL-6-induced pro-inflammatory outcomes., IL-6 levels are upregulated during cerebral ischemia, which correlates with infarct volumes and survival rates., Interestingly, IL-6 levels are seemingly upregulated by IL-1β. The fact that brain-derived IL-6 promotes neurogenesis after stroke, and thus contributes to long-term functional recovery, points to its potential neuroprotective effect following cerebral ischemia. Even though only a few studies have focused on the role of IL-6 in ischemic stroke, its pleiotropic effects are worth further investigation.

51Contrary to the aforementioned pro-inflammatory cytokines, IL-10 is released primarily by type-2 helper T cells and serves as an anti-inflammatory cytokine, reducing inflammation and limiting cellular apoptosis. IL-10 gene polymorphism is associated with the risk of stroke subtypes. In experimental ischemic stroke models, transgenic mice with enhanced IL-10 expression showed reduced infarct volumes and cellular apoptosis. Likewise, clinical studies have shown that low IL-10 levels correlate with poor stroke outcomes, worse neurological deficits, and extravagated inflammatory reactions.– These results indicate that the anti-inflammatory properties of IL-10 serve as a potential clue for the diagnosis and prognosis of ischemic stroke.

Chemokines

52In addition to cytokines, chemokines represent another group of small signaling proteins that contributes to the inflammatory processes in ischemic stroke. Immediately after cerebral ischemia, pro-inflammatory cytokines, such as TNF-α and IL-1β, induce the secretion of chemokines, such as MCP-1, fractalkine, macrophage inflammatory protein 1, microglial response factor-1, and cytokine-induced neutrophil chemoattractant. Chemokine-chemokine ligand 2 (CCL2) and its corresponding receptor, CCR2, are involved in regulating the inflammatory response in ischemia, possibly via immune cell recruitment and adhesion to cerebral endothelial cells., CCL2 expression becomes enhanced in the ischemic penumbra, cerebrospinal fluid, and serum after ischemia or ischemia-reperfusion., Moreover, CCL2/CCR2 expression correlates positively with infarct area and lesion enlargement,, and enhanced CCL2 expression further aggravates ischemic injury in mice. Ischemic damage significantly increased MCP-1 mRNA (CCL2) expression, which further exacerbated ischemic brain injury, together with abundant infiltration of inflammatory cells in an experimental ischemic stroke model. All these findings suggest the detrimental role that CCL2/CCR2 signaling pathways play in ischemic stroke.

53Besides the most frequently discussed CCL2, other chemokines are also involved in the pathogenesis of ischemic stroke. For instance, CCL3 has been reported to be upregulated in experimental ischemic stroke models. Consistently, external administration of CCL3 to brain ventricles exacerbated ischemia-induced injuries. Meanwhile, another chemokine CCL5 has been found to regulate ischemia/reperfusion (I/R) injuries in experimental ischemic stroke models. Clinical studies have also shown that plasma CCL5 levels were increased in symptomatic patients in comparison with asymptomatic ones. Besides the CC chemokine family, the CXC chemokines, also plays crucial roles in ischemic stroke pathogenesis. Among them, those ELR+ CXC chemokines, including CXCL1, CXCL2, and CXCL8, directly function to neutrophils toward ischemic brain regions; however, those ELR− CXC chemokines, including CXCL10, CXCL12, and CXCL16, mainly induce Th1-cell infiltration in postischemic inflammation.

High-mobility group box protein 1 (HMGB1)/Toll-like receptor (TLR) and NF-κB signaling pathways in neuroinflammation

54Various immune cells, as well as the corresponding cellular products, are associated with oxidative stress and necrosis activate the innate immune system, probably via the TLR signaling pathway. TLRs, which are expressed on both the cell surface and in the intracellular space, regulate the status and function of numerous immune cells.– TLR signaling can be categorized based on two major downstream adaptor proteins: myeloid differentiation primary response 88 (MyD88)-dependent and adapter-inducing interferon-β-dependent pathways. Both TLR signaling pathways activate NF-κB, which subsequently triggers the release of pro-inflammatory cytokines.–

55Interestingly, TLRs may act as another double-edged sword in ischemic stroke. In case of relatively moderate ischemic injury, TLR2 and TLR4/NF-κB signaling pathways are inhibited, whereas interferon regulatory factor 3 signaling is enhanced. Both of these processes exert neuroprotective effects on ischemia. Pretreatment with TLR2, TLR3, TLR4, TLR7, or TLR9 agonists alleviates the symptoms and pathological damage in various ischemic stroke models., Administration of lipopolysaccharide prior to ischemic insult protects against cerebral ischemia, possibly by modulating the TLR4 signaling pathway and inhibiting NF-κB after ischemic stroke attack. In contrast, elevated levels of plasma lipopolysaccharide appear to promote the expression of TLR4, causing the release of inflammatory cytokines, larger infarct volumes, and more severe functional deficits in rat cerebral ischemia models. These seemingly contradictory results suggest that LPS modulation of TLR4 response possibly depends on whether activation occurs before or after ischemic insult.

56One key component in the TLR-related signaling pathway is HMGB1, which triggers downstream neuroinflammatory responses during stroke. HMGB1 levels are significantly elevated in the brain, specifically in microglia, astrocytes, and blood vessel cells, which are closely associated with neuroinflammation and cellular stress such as stroke.– As one of the major ligands for TLRs, extracellular HMGB1 interacts with TLR2 or TLR4 and in turn NF-κB to elicit pro-inflammatory reactions.,, Moreover, the release of HMGB1 activates TLR4 and enhances IL-1β production through Nod-like receptor protein 3 (NLRP3) inflammasome activation. Furthermore, HMGB1 enhances the secretion of several pro-inflammatory cytokines, including inducible NOS, cytochrome c oxidase subunit 2, IL-1β, and TNF-α, promoting neuronal cell death during ischemia. These results suggest that both inflammatory reactions and cell death signaling pathways are induced by HMGB1/TLR signals in ischemic stroke, possibly aggravating ischemic injury.

MAPK signaling pathway in inflammation and BBB dysfunction

57MAPK comprises three main effectors: ERK1/2, JNK, and p38. Stress-activated protein kinases, JNK, p38 MAPK, and ERK exert detrimental effects during cerebral ischemia. Specifically, the MAPK signaling pathway is activated soon after the onset of ischemic injury, and p38 MAPK regulates the expression of various pro-inflammatory cytokines. Activation of the p38/MAPK/AR-related signaling pathway has been shown to promote the microglial pro-inflammatory phenotype in cerebral ischemia. Activation of MAPK/ERK signaling and consequent stimulation of metalloproteinase (MMP) expression could exacerbate BBB damage in ischemic stroke, further enhancing the expression of pro-inflammatory factors. Similarly, BBB damage in cerebral ischemia induced by a high-salt diet, has been associated with the p38/MAPK/SGK1 signaling pathway. These results suggest that MAPK-related signaling pathways exacerbate ischemic brain injury, possibly by enhancing neuroinflammatory processes and BBB dysfunction.

MMPs and BBB dysfunction in ischemic stroke

58MMPs are crucial for the function and structure of the BBB in both human and animal stroke models., The elevated production of MMPs and myeloperoxidase in ischemic stroke favors BBB breakdown. In particular, MMP9 induces proteolysis of the BBB basal lamina., Clinical studies have shown that baseline MMP9 serves as an important indicator of BBB disruption in ischemic stroke and is related to the hyperintense acute reperfusion injury marker used in magnetic resonance imaging. Hypothermia followed by rapid rewarming enhances the permeability of the BBB in ischemic stroke, along with elevated MMP9 expression levels and damage to tight junctions. MMP12 levels have been found to be elevated in rat cerebral ischemic stroke models, whereas suppressing MMP12 alleviates the symptoms induced by ischemia. Concurrently, MMP2 may participate in the pathophysiology of ischemic stroke, together with VEGF signaling. The latter is likely involved in the initial stages of ischemic stroke, whereby hypoxic preconditioning exacerbates BBB injury and brain edema. Furthermore, it has been shown that recovery from BBB damage is associated with both the MMP2 and VEGF pathways in acute cerebral ischemia, suggesting a close link between MMP2 and VEGF.

Sphingosine-1-phosphate receptor (S1PR)-related signaling pathways during neuroinflammation in ischemic stroke

59S1PRs form a group of G protein-coupled receptors abundant in microglia and are thought to regulate inflammatory responses in ischemic stroke. In vitro studies have shown that the addition of S1P to microglia subjected to oxygen-glucose deprivation/reperfusion exacerbates hypoxia-induced neuronal apoptosis. In experimental ischemic stroke models, sphingosine kinase 1 phosphorylates sphingosine to S1P, which binds to S1PR3 and confers microglia a pro-inflammatory phenotype. Sphingosine kinase 1 enlarges the brain infarct volume and exacerbates neurological symptoms by upregulating the expression of pro-inflammatory cytokines. Intriguingly, the S1PR agonist fingolimod has been recently reported to switch microglia from a pro-inflammatory to an alternatively activated phenotype in a chronic hypo-perfused ischemic stroke model in mice. Thus, the pro-inflammatory mechanism of S1PRs in ischemic stroke requires further exploration.

Inflammasome activation in ischemic stroke

60Inflammasomes are large multiprotein complexes,, which can mediate neuroinflammation and contribute to neural cell death in ischemic stroke. Both in vivo and in vitro model studies suggest that the NLRP3 inflammasome plays a pivotal role in microglia-associated neuroinflammation in ischemic stroke, possibly through alterations to the microglial phenotype. These effects may be linked to activation of the NF-κB signaling pathway. Additionally, NLRP1 is related to cerebral ischemic injuries, and its inhibition alleviates neuroinflammation in ischemia. Thus, inflammasome activation, either via NLRP1 or NLRP3, contributes to the pathogenesis of ischemic stroke and could provide a therapeutic target against cerebral ischemia.

Microglial phagocytosis and complement activation

61Microglia functions as the major phagocyte in the central nervous system, which is responsible for myelin debris clearance and pruning synapsis. It has been reported that microglia phagocytose tissue debris in experimental ischemic stroke model, which contribute to tissue repair and neuronal network reconstruction., However, other studies have also pointed out that over-enhanced microglia engulfment exacerbates cerebral ischemia-induced brain injuries., Hence, microglial phagocytosis may play both beneficial or detrimental roles in ischemic stroke. Microglia could engulf a variety of dying cells and debris, in which a plethora of signaling pathways are involved. TMEM16F is expressed by stressed neurons in ischemic stroke, which induces neurons to expose phospholipid phosphatidylserine (PS), an ‘eat-me’ signal. Consistently, knockdown of TMEM16F hindered microglial phagocytosing viable neurons in the penumbra after experimental ischemic stroke. Besides, triggering receptor expressed on myeloid cells (TREM2) signaling pathways are deemed to be greatly involved in microglial phagocytosis in ischemic stroke. TREM2 deficiency dampens microglial phagocytosis of neurons, which further exacerbates ischemic brain injuries, indicated the neuroprotective role of Trem2 in ischemic stroke.

62Another part of phagocytosis is the complement system, including C1q and C3. Upon activation, C3 is cleaved into C3a and C3b, of which C3b as well as its receptor, CR3, function together to regulate dying cells clearance., Meanwhile, C1q, the biggest component of the C1 complex, has been reported to strengthen microglial clearance of apoptotic cells in ischemic stroke. After ischemic stroke, microglial phagocytosis of both synapses and neurons was directed by activation of complement, which eventually contributes to cognitive decline., Thus, with a variety of signaling pathways involved, activation of the complement system may also be closely interacted with microglial phagocytosis, which possibly, greatly influence the pathologies of ischemic stroke.

Therapeutic approaches targeting pathophysiological signaling pathways involved in ischemic stroke

63So far, the only drug approved by FDA for treating ischemic stroke is tissue plasminogen activator (tPA), which breaks down the blood vessel clot. This therapy has several limitations, such as the therapeutic window is only 4.5 h, and treatment outside the therapeutic window could possibly result in cerebral hemorrhage. Progress have been made in discovering new therapeutic approaches against ischemic stroke. Current studies have shed lights on micro-RNA therapies, in which expression levels of miRNA are changed and apoptosis-related genes are subsequently mediated. Another potential treatment is cell therapy, which utilizes stem cells to differentiate. However, therapeutic approach is quite limited, and more research are need to discover new potential therapeutic strategy for ischemic stroke.

64Given the pivotal roles the pathophysiology and signaling pathways play in ischemic stroke, numerous therapeutic approaches have been explored in both experimental and clinical studies, and several of them have been demonstrated to be effective in treatment of ischemic stroke (Table 2).

Targeting the GluN2B-PSD95-nNOS complex

65The GluN2B-PSD95-nNOS complex plays a central role in regulating NMDAR activity and related signaling pathways; therefore, it could potentially serve as a therapeutic target for cerebral ischemic stroke. The Tat-NR2B9c peptide, which binds to either PSD95 or nNOS, was shown to prevent downstream neurotoxic pathways and superoxide production. Furthermore, Tat-NR2B9c administration reportedly improved behavioral deficits, reduced infarct volumes, and retained the gene transcription profiles in animal ischemic stroke models., Another study reported that TAT-NR2B9c alleviated neuronal death and p38-induced damage in ischemic injury, while a clinical study found that it significantly decreased infarcts in ischemic stroke patients. Another small molecule called ZL006 has been found to disrupt the interaction between PSD95 and nNOS in ischemia, without affecting the normal functions of NMDARs and nNOS., Similarly, IC87201 has been found to disrupt pathogenic interactions between PSD95 and nNOS but without impairing normal nNOS activities. Finally, a study has shed light on Neu2000, a sulfasalazine derivative and GluN2B antagonist that selectively blocks NMDARs and scavenges free radicals, which exerted a neuroprotective effect in ischemic stroke., All this experimental evidence highlights the potential of treating ischemic stroke by targeting the GluN2B-PSD95-nNOS complex and preventing its participation in excitotoxicity. However, several shortcomings still exist. Although overactivation of NMDARs is acknowledged to be important in the etiology of cerebrovascular insults, the importance in physiological function has made the current NMDAR antagonists ‘undruggable’ for clinical application in ischemic stroke., Also, the therapeutic time window is relatively short, and safety issues including nausea, vomiting, cardiovascular and psychomimetic effects, remain to be considered.–

Targeting the DAPK1 signaling pathway

66DAPK1 phosphorylates p53, a tumor suppressor that serves as one of its substrates. The interfering peptide Tat-p53DM241–281 inhibits specifically the downstream targets of DAPK1, such as the pro-apoptotic genes Bax, Puma, and caspase-3, which are also regulated by p53. The administration of Tat-p53DM241–281 was observed to significantly reduce infarct area and alleviate behavioral deficits in experimental ischemic stroke models. Another drug, GluN2BCT1292–1304, dissociates DAPK1 from the GluN2B subunit and protects neurons from ischemic injury. However, it still remains controversial that McQueen et al. have found that genetic depletion of DAPK1 could not alleviate excitotoxic and ischemic injuries in neurons. With possible uncertainties, these results indicate that DAPK1 inhibition could potentially alleviate ischemic brain damage through decreasing cellular excitotoxicity.

Targeting the PTEN-induced signaling pathway

67Based on the function of PTEN in inhibiting the PI3K/Akt signaling pathway and inducing apoptotic cell death via excitotoxicity, regulating PTEN could possibly help ameliorate excitotoxicity and, in turn, neurological deficits in ischemic stroke. Genetic knockdown of PTEN was found to retain PI3K/Akt signaling while downregulating the extra-synaptic NMDAR current, which exerted a neuroprotective effect on an experimental ischemic stroke model. Pharmacologically, an interfering peptide, Tat-K13, was utilized to disrupt the cell death signaling pathway activated by PTEN. Tat-K13 exerted a neuroprotective effect in rats suffering from experimental ischemic stroke by reducing the size of the infarct lesion., These findings suggest that, owing to its link to PI3K/Akt signaling, the PTEN-related pathway could serve as a potential therapeutic target in the treatment of ischemic stroke.

Targeting the AKT signaling pathway

68The iridoid glycoside geniposide has been reported to protect neurons from ischemic damage by activating the GluN2A/AKT/ERK signaling pathway. Accordingly, pseudoginsenoside-F11 prevents calpain1 activation while promoting the GluN2A-mediated AKT/CREB pathway. Genes involved in the modulation of NMDAR expression along the Akt/ERK pathway could also potentially serve as therapeutic targets. TRPM2 knockout mice showed significantly smaller ischemic lesions, altered expression of GluN2A and GluN2B, and stimulation of pro-survival Akt and ERK signaling in an experimental ischemic stroke model. Overall, therapeutic approaches involving drugs, physical treatment, or gene modifications enhancing AKT-related signaling pathways and NMDAR activities could reinforce synaptic NMDAR activities and their neuroprotective effects in ischemic stroke.

Targeting the Panx1 signaling pathway

69During ischemia, NMDAR activates Src kinases, which subsequently phosphorylate residue Y308 in the C-terminus of pannexin 1 (Panx1), leading to secondary ischemic currents., Preventing Panx1 phosphorylation may alleviate the symptoms and pathologies of ischemic stroke. Indeed, use of the interfering peptide Tat-Panx308 helped reduce infarct lesion size and alleviate sensorimotor deficit symptoms in middle cerebral artery occlusion (MCAO) rats, suggesting its effectiveness in treating ischemic stroke. In spite of the limited number of studies, regulation of Panx1 in excitotoxicity could represent a promising strategy for ischemic stroke treatment.

Nrf2/ARE signaling pathway

70The Nrf2/ARE signaling pathway contributes to the generation of numerous protective factors, such as anti-inflammatory proteins, antioxidant enzymes, and growth factors. Its antioxidant target genes include those encoding for heme oxygenase 1 (HO1), NADP(H) quinone dehydrogenase 1 (NQO1), and glutathione S-transferase (GST). Thus, regulation of the Nrf2/ARE signaling pathway could potentially protect against oxidative stress-induced damage in ischemic stroke. It has been reported that injection of tBHQ, an Nrf2 inducer, alleviates the symptoms of experimental cerebral ischemic stroke. Similarly, administration of metformin in cerebral ischemic stroke models alleviated oxidative stress-induced BBB damage, possibly through activation of the NRF2/ARE signaling pathway. In contrast, higher vulnerability and exacerbated brain damage were observed in cerebral ischemic stroke models of Nrf2-knockout mice. Generally, activating the Nrf2/ARE signaling pathway may confer a neuroprotective effect in cerebral ischemic stroke, which is associated with mitigation of oxidative stress.

Sirtuin (SIRT)/forkhead box O (FOXO) signaling pathway

71SIRT1–7 play important roles in oxidative stress during ischemic stroke. The SIRT/FOXO signaling pathway has been shown to prevent oxidative stress in cerebral ischemia-reperfusion. SIRT1 exerts an antioxidant effect by activating either the FOXO family or PPAR-γ coactivator-1 and, as such, could serve as a potential therapeutic target., SIRT3 has been reported to enhance SOD2 activity and decrease ROS levels. Moreover, transsodium crocetinate protected animals from oxidative stress induced by cerebral ischemia–reperfusion injury, probably by activating the SIRT3/FOXO3a/SOD2 signaling pathway. Similarly, genipin was found to regulate the UCP2/SIRT3 signaling pathway and alleviate oxidative stress induced by cerebral ischemia. These findings reveal the potential of SIRT signaling pathways in therapeutic approaches against oxidative stress and ischemic stroke.

Chemokine-related signaling pathways

72Therapeutic approaches regulating CCL2/CCR2 expression may alleviate the symptoms and pathologies of ischemic stroke. Whereas CCL2 gene disruption reduced infarct volume, CCR2 deletion reduced infarct size, while also improving locomotor ability of mice in an experimental ischemic stroke model., CCR knockout reduced infarct volumes and mortality of mice in experimental ischemic stroke models. However, it should be mentioned that hindering monocyte infiltration using an anti-CCR2 antibody delayed long-term behavioral recovery, along with decreased expression of anti-inflammatory genes in MCAO mice, suggesting a double-edged role of CCL2/CCR2 in ischemic stroke. Infarct size in rat MCAO models has been reduced also via inhibition of another chemokine, CCL23 (also known as MIP3α). Taken together, regulating chemokine expression, especially the CCL2/CCR2 signaling pathway, may serve as a potential therapeutic approach against cerebral ischemic stroke, although the harmful effects of such an intervention should be carefully considered.

TLR-associated signaling pathways

73Considering the important role played by TLRs in neuroinflammation, several studies have demonstrated that TLR signaling could serve as a treatment target. Overexpression of miR-18a-5p downregulates the levels of TLR4 and TLR7, exerting a protective effect against ischemic injury in vitro. Resveratrol modulates microglial activity and improves ischemia-induced neurological symptoms by regulating the TLR4/NF-κB/STAT3 signaling pathway.– Stevioside, a natural glycoside, protects against cerebral ischemia by inhibiting TLR/NF-κB pathway-mediated neuroinflammation. Moreover, treatment with progesterone and its metabolites has been shown to alleviate the symptoms of various cerebrovascular diseases by regulating the TLR4/NF-κB signaling pathway and inhibiting neuroinflammation.– Similarly, dexmedetomidine has been proven effective against inflammatory reactions, oxidative stress, increased infarct volume, and brain edema in MCAO rats by inhibiting the HMGB1/TLR4/NF-κB signaling pathway. Interestingly, one study reported that activating TLR7 reduced infarct volume and neurological deficits by enhancing interferon expression. This observation is possibly associated with the dual effect of TLRs on neuroinflammation and ischemic stroke. In conclusion, regulation of TLR signaling has been revealed to attenuate neuroinflammation and, thus, protect against ischemic stroke. This therapeutic effect is possibly related to a variety of downstream molecules, including NF-κB and STAT3, whose modulation could promote the beneficial effects of TLRs in ischemic stroke.

Cytokine-related signaling pathways

74Regulation of IL-1 and TNF cytokine families could also help attenuate ischemic stroke injuries. A study using a single intravenous dose of XPro1595 or etanercept, which targets TNFs, found that both compounds alleviated inflammatory reactions and enhanced locomotor abilities in a mouse model of focal cerebral ischemia; however, they did not decrease infarct volume. Another modified therapy, cTfRMAb-TNFR, which transfers TNFR across the BBB, has been reported to successfully reduce the infarct area and ameliorate neurological deficits., Similarly, a preclinical study demonstrated that sTNF-αR1 retained axonal plasticity in the cerebral cortex after stroke, which is in agreement with the results of another study showing that injection of solTNFR1 in dendritic cells alleviated infarct injury and inflammation after experimental stroke. However, it’s still worth mentioning that targeting both solTNF and tmTNF may concurrently raise the risk of cardiovascular and demyelinating disease. Due to the possible side effects of the anti-TNF therapies, more efforts should be made for more specific anti-TNF therapeutics.

75IL-1Ra is the only therapeutic agent against IL-1-associated inflammation. Preclinical studies have shown that recombinant IL-1Ra protects against ischemia-induced injuries in rats, and mice. Concomitantly, the first randomized, double-blind, placebo-controlled trial utilizing recombinant human IL-1Ra showed that patients receiving rhIL-1Ra displayed milder inflammatory reactions and nearly no disability 3 months after stroke. There’re several shortcomings that rhIL-1Ra crosses the BBB slowly and has relatively short half-life in the circulation to achieve effective and persistent therapeutic concentration., Also, there’re studies showing that IL-1Ra increased the possibility of poor mRS outcomes. Though that, IL-1Ra still has good perspectives in cerebral ischemic stroke treatment owing to its anti-inflammatory properties.

NLRP3 inflammasome

76NLRP3 inflammasome regulation has been acknowledged as a potential therapeutic approach for ischemic stroke. Brilliant blue G, a P2X7R purinergic receptor antagonist, or MCC950, an NLRP3 inhibitor, not only attenuated cerebral infarct areas and neurological impairments but also inhibited caspase-3-associated neuronal apoptosis. Similarly, genistein, a natural phytoestrogen, has been reported to alleviate cerebral ischemia-induced injury in senescent mice by inhibiting NLRP3 inflammasome formation. An in vitro study revealed that treatment modulating the immunoproteasome/NF-κB/NLRP3 inflammasome signaling axis could work against hypoxia and ischemia, as well as prevent apoptosis. Therefore, inhibition of NLRP3 inflammasome formation could possibly attenuate ischemic stroke inflammatory processes and limit cell death.

Sirt signaling pathways

77Protecting the BBB could help alleviate ischemic stroke. In an experimental rat model of stroke, hyperbaric oxygen treatment helped protect the BBB, potentially by regulating the ATP/NAD+/Sirt1 signaling pathway. Similarly, quercetin has been shown to protect the BBB and alleviate ischemia–reperfusion-induced injuries via activation of Sirt1 signals in rats. Minocycline has also been shown to ameliorate hypoxia-induced BBB disruption. This effect was mediated by the Sirt3/proline hydroxylase-2 degradation pathway, together with decreased levels of MMP2, MMP9, and VEGF, as well as upregulation of tight junction proteins.

MMP inhibition for BBB protection

78Given the indispensable role of MMPs, inhibition of the MMP signaling pathway may be beneficial in anti-stroke therapy. Administration of hydrogen sulfide donors may help ameliorate cerebral BBB damage, most likely via MMP9 inhibition. In addition, vagus nerve stimulation could help protect the BBB in ischemic damage by inhibiting MMP2/9-mediated tight junction protein disruption. Similarly, hyperbaric oxygen has been reported to stabilize the BBB in an experimental ischemic stroke model, possibly by blocking MMP2 activation. Finally, intra-arterial norcantharidin alleviated cerebral BBB damage by decreasing MMP9 expression in an experimental ischemic stroke model. These results suggest that regulation of MMP-related signaling pathways protects the BBB from ischemic stroke injuries.

Autophagy-related signaling pathways

79A variety of signaling pathways related with autophagy, including Akt, AMPK, and others, has been shown to be potential therapeutic approaches against ischemic stroke. Fingolimod, a well-established sphingosine-1-phosphate receptor agonist, alleviates neurological deficits and reduces infarct areas by enhancing Akt signaling and ameliorating neuronal apoptosis,, as well as regulating the mTOR/p70S6K autophagy signaling pathway in ischemic stroke models. Studies have also reported that selenium protects the BBB from ischemia-reperfusion injuries associated with PI3K/mTOR/AKT signaling pathway activation, which is possibly related to autophagy inhibition., As for the AMPK signaling pathway, SMXZF, a combination of Rb1, Rg1, schizandrin, and DT-13 (6:9:5:4), exerts a neuroprotective effect on cerebral ischemia-reperfusion injury, possibly by suppressing autophagy through regulation of the AMPK/mTOR and JNK signaling pathways, both in animals and oxygen-glucose deprivation/reperfusion models., Likewise, by activating AMPK-induced autophagy, ezetimibe ameliorates neuronal apoptosis and infarct volume, while improving neurological deficits in MCAO rat models. Finally, physical exercise induces AMPK activation and mTORC1 inhibition, thereby promoting autophagy, which consequently improves cerebral ischemia outcomes.–

80Besides these two main target signals, additional autophagy-associated signaling pathways, related mainly to STAT, and SIRT, could also serve as targets for ischemic stroke therapies. Extracellular vesicles secreted by stem cells help mitigate ischemic brain damage, possibly by modulating STAT3-dependent autophagy, both in vivo and in vitro. In an experimental rat cerebral ischemia-reperfusion injury model, electroacupuncture mitigated neurological symptoms and related pathologies through inhibition of maladaptive autophagy and activation of the SIRT/FOXO1 signaling pathway., In addition, other signaling pathways involving SIRT, including SIRT3/AMPK/mTOR and SIRT1/BMAL1, are activated by luteolin and melatonin, respectively, and help protect against cerebral ischemia–reperfusion-induced injuries.,

Apoptosis-associated signaling pathways

81Likewise, regulation of several signaling pathways, such as ERK/MAPK, AMPK and SIRT signaling pathways, are shown to mediate apoptosis in ischemic stroke. Beta-hydroxybutyrate ameliorates cerebral ischemic stroke injuries by suppressing apoptosis induced via oxidative stress and mitochondrial dysfunction, both in vivo and in vitro. The curative effects on apoptosis are probably associated with ERK/CREB/eNOS signaling pathway activation. Modulation of other ERK/MAPK signaling axes, including the MAPK/ERK/EGR1, CXCL13/ERK/MEK, and DAPK1/ERK signaling pathways, has also been shown to protect against ischemia-induced injuries both in vitro and in vivo.– With respect to the AMPK signaling pathways, BML-275, an AMPK inhibitor, exerts a neuroprotective effect on cerebral ischemic stroke by downregulating cytochrome c and AIF expression, consequently blocking apoptosis. In addition, glycine was shown to attenuate cellular apoptosis and improve ischemic stroke damage by suppressing the AMPK/GSK3β/HO1 signaling pathway. SIRT signals are also possibly involved, as Rosuvastatin may exert protective effects on cerebral ischemia in rats through the Sirt1/NF-κB signaling pathway and inhibition of apoptosis. Stem cell therapies also attenuate ischemia-induced injuries, potentially through the SIRT/NF-κB signaling pathway. Finally, an in vitro study revealed that regulation of the miRNA-29b/SIRT1/PPAR-γ coactivator 1 alpha axis ameliorated oxygen-glucose deprivation-induced cell apoptosis, thus protecting cells from ischemia. All these reveal the potential of therapeutics against cellular apoptosis in ischemic stroke.

National clinical trials of therapeutic approaches targeting ischemic stroke and signaling pathways

82Clinical trials targeting the pathophysiology and the related signaling pathways mentioned above have been implemented with respect to ischemic stroke. For instance, the value of targeting cellular excitotoxicity in ischemic stroke has been recognized by investigators pursuing clinical trials with nerinetine (NA-1), the inhibitor of GluN2B-PSD95-nNOS complex (NCT02930018, NCT04462536, NCT00728182, NCT02315443), Neu2000 (NCT04486430), and sofadil (NCT04453800). In addition, several clinical trials focused on neuroinflammation during ischemic stroke have also been implemented, including those targeted IL-1 (NCT04834388, NCT03737344), S1P receptors (NCT02002390), and Toll-like receptors (TLRs) (NCT04734548). Furthermore, therapeutic approaches targeting oxidative stress in ischemic stroke have also been tested in clinical trials, such as selenium (NCT02505295), astaxanthine (NCT03945526), and simavastatin (NCT03402204). Concurrently, stem cell therapy is attracting much attention due to its potential for exerting significant therapeutic effects on stroke patients. Various types of cells, including allogenic mesenchymal stem cells from adipose tissue(NCT01678534), bone-marrow-derived stem cell (NCT01501773), endothelial progenitor cells (NCT01468064), and autologous M2 macrophages (NCT018453500) have been tested in clinical trials as a reparative therapy for acute ischemic stroke. All these reveal prospects for targeting the pathophysiology and related signaling pathways in treating ischemic stroke.

Concluding remarks and future perspectives

83Ischemic stroke is characterized by the blockade of cerebral blood flow caused by the presence of thrombi in the blood vessels and has an overwhelming effect on people’s health and their quality of life. In recent years, studies have sought to further elucidate the mechanisms of ischemic stroke. Nevertheless, the complex pathogenesis of ischemic stroke means that the participating signaling pathways need further comprehensive exploration. In this review, we summarized the signaling pathways involved in ischemic stroke and categorized them based on their specific pathophysiological roles in excitotoxicity, mitochondrial dysfunction, oxidative stress, neuroinflammation, and cell death. Because these signaling pathways are interconnected, combined therapeutic targets against ischemic stroke may be elucidated.

84At present, recanalization of blood vessels via intravenous thrombolytic treatment or mechanical thrombectomy represents the major therapeutic approach for ischemic stroke. However, this is underscored by the lack of suitable pharmacological treatments, calling for the discovery of new therapeutic targets against ischemic stroke. In this review, we combed through existing therapeutic approaches and classified them according to their target signaling pathways. In conclusion, our review comprehensively elucidates the signaling pathways involved in the pathophysiology of ischemic stroke and also points out potential therapeutic approaches against ischemic stroke associated with those key signaling pathways.

References 455

1.
Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67:181-198.
Not in our library10.1016/j.neuron.2010.07.002
2.
Feigin VL, et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383:245-255.
Not in our library10.1016/s0140-6736(13)61953-4
3.
Kleindorfer DO, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021;52:E364-E467.
Not in our library10.1161/str.0000000000000375
4.
Adams HP, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
Not in our library10.1161/01.str.24.1.35
5.
Hankey GJ. Stroke. Lancet. 2017;389:641-654.
Not in our library10.1016/s0140-6736(16)30962-x
6.
Nguyen, T.-V. V. et al. Multiplex immunoassay characterization and species comparison of inflammation in acute and non-acute ischemic infarcts in human and mouse brain tissue. Acta Neuropathol. Comm. 4, (2016).
Not in our library10.1186/s40478-016-0371-y
7.
Park JY, et al. Neuroprotective effect of human placental extract on hypoxic-ischemic brain injury in neonatal rats. Brain Dev. 2013;35:68-74.
Not in our library10.1016/j.braindev.2012.01.009
8.
Barthels, D. & Das, H. Current advances in ischemic stroke research and therapies. Biochimica Et Biophysica Acta-Mol. Basis Dis. 1866, (2020).
Not in our library10.1016/j.bbadis.2018.09.012
9.
Yenari MA, Kauppinen TM, Swanson RA. Microglial activation in stroke: therapeutic targets. Neurotherapeutics. 2010;7:378-391.
Not in our library10.1016/j.nurt.2010.07.005
10.
Koyama Y. Signaling molecules regulating phenotypic conversions of astrocytes and glial scar formation in damaged nerve tissues. Neurochem. Int. 2014;78:35-42.
Not in our library10.1016/j.neuint.2014.08.005
11.
Sims NR, Yew WP. Reactive astrogliosis in stroke: Contributions of astrocytes to recovery of neurological function. Neurochem. Int. 2017;107:88-103.
Not in our library10.1016/j.neuint.2016.12.016
12.
Slujitoru A-S, et al. Clinical and morphological correlations in acute ischemic stroke. Rom. J. Morphol. Embryol. 2012;53:917-926.
Not in our library
13.
Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic Stroke · 2013
Corrected
14.
Jin R, et al. Role of inflammation and its mediators in acute ischemic stroke. J. Cardiovasc. Transl. Res. 2013;6:834-851.
Not in our library10.1007/s12265-013-9508-6
15.
Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice · 2008
No notice
16.
Leukocyte infiltration in experimental stroke · 2013
No notice
17.
Functional differences between microglia and monocytes after ischemic stroke · 2015
No notice
18.
Ischemic stroke: experimental models and reality · 2017
No notice
19.
Smith HK, Russell JM, Granger DN, Gavins FNE. Critical differences between two classical surgical approaches for middle cerebral artery occlusion-induced stroke in mice. J. Neurosci. Methods. 2015;249:99-105.
Not in our library10.1016/j.jneumeth.2015.04.008
20.
Knowland D, et al. Stepwise Recruitment Of Transcellular And Paracellular Pathways Underlies Blood-brain Barrier Breakdown In Stroke. Neuron. 2014;82:603-617.
Not in our library10.1016/j.neuron.2014.03.003
21.
Huang L, et al. Human neural stem cells rapidly ameliorate symptomatic inflammation in early-stage ischemic-reperfusion cerebral injury. Stem Cell. Res. Ther. 2014;5:129.
Not in our library10.1186/scrt519
22.
Qian C, et al. Precise characterization of the penumbra revealed by MRI: a modified photothrombotic stroke model study. PLoS One. 2016;11:e153756.
Not in our library10.1371/journal.pone.0153756
23.
Yang, L., Shah, K. K. & Abbruscato, T. J. In Astrocytes: Methods and Protocols Vol. 814 Methods in Molecular Biology (ed R. Milner) 451–466 (2012).
Not in our library10.1007/978-1-61779-452-0_30
24.
Li D, et al. mTORC1 pathway disruption ameliorates brain inflammation following stroke via a shift in microglia phenotype from M1 type to M2 type. FASEB J. 2016;30:3388-3399.
Not in our library10.1096/fj.201600495r
25.
Li K, et al. Middle East Respiratory Syndrome Coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl Peptidase 4. J. Infect. Dis. 2016;213:712-722.
Not in our library10.1093/infdis/jiv499
26.
Xiong X-Y, Liu L, Yang Q-W. Refocusing neuroprotection in cerebral reperfusion era: new challenges and strategies. Front. Neurol. 2018;9:249.
Not in our library10.3389/fneur.2018.00249
27.
Lai TW, Zhang S, Wang YT. Excitotoxicity and stroke: Identifying novel targets for neuroprotection. Prog. Neurobiol. 2014;115:157-188.
Not in our library10.1016/j.pneurobio.2013.11.006
28.
Jia J, et al. New insights into targeting mitochondria in ischemic injury. Apoptosis. 2021;26:163-183.
Not in our library10.1007/s10495-021-01661-5
29.
Macrez R, et al. Stroke and the immune system: from pathophysiology to new therapeutic strategies. Lancet Neurol. 2011;10:471-480.
Not in our library10.1016/s1474-4422(11)70066-7
30.
Steliga A, et al. Neurovascular unit as a source of ischemic stroke biomarkers-limitations of experimental studies and perspectives for clinical application. Transl. Stroke Res. 2020;11:553-579.
Not in our library10.1007/s12975-019-00744-5
31.
Datta A, et al. Cell Death Pathways In Ischemic Stroke And Targeted Pharmacotherapy. Transl. Stroke Res. 2020;11:1185-1202.
Not in our library10.1007/s12975-020-00806-z
32.
Andrabi SS, Parvez S, Tabassum H. Ischemic stroke and mitochondria: mechanisms and targets. Protoplasma. 2020;257:335-343.
Not in our library10.1007/s00709-019-01439-2
33.
Targeting NMDA receptors in stroke: new hope in neuroprotection · 2018
No notice
34.
Olney JW. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science. 1969;164:719-721.
Not in our library10.1126/science.164.3880.719
35.
Garthwaite G, Williams GD, Garthwaite J. Glutamate toxicity: an experimental and theoretical analysis. Eur. J. Neurosci. 1992;4:353-360.
Not in our library10.1111/j.1460-9568.1992.tb00882.x
36.
Choi DW, Koh JY, Peters S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J. Neurosci. 1988;8:185-196.
Not in our library10.1523/jneurosci.08-01-00185.1988
37.
Willard SS, Koochekpour S. Glutamate, glutamate receptors, and downstream signaling pathways. Int. J. Biol. Sci. 2013;9:948-959.
Not in our library10.7150/ijbs.6426
38.
George PM, Steinberg GK. Novel Stroke Therapeutics: Unraveling Stroke Pathophysiology And Its Impact On Clinical Treatments. Neuron. 2015;87:297-309.
Not in our library10.1016/j.neuron.2015.05.041
39.
Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: New opportunities for novel therapeutics. J. Cereb. Blood Flow. Metab. 1999;19:819-834.
Not in our library10.1097/00004647-199908000-00001
40.
Lipton P. Ischemic cell death in brain neurons. Physiol. Rev. 1999;79:1431-1568.
Not in our library10.1152/physrev.1999.79.4.1431
41.
Mazala DAG, Grange RW, Chin ER. The role of proteases in excitation-contraction coupling failure in muscular dystrophy. Am. J. Physiol. Cell. Physiol. 2015;308:C33-C40.
Not in our library10.1152/ajpcell.00267.2013
42.
Weber JT. Altered calcium signaling following traumatic brain injury. Front. Pharmacol. 2012;3:60.
Not in our library10.3389/fphar.2012.00060
43.
Xu J, et al. Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J. Neurosci. 2009;29:9330-9343.
Not in our library10.1523/jneurosci.2212-09.2009
44.
Casas AI, et al. Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke. J. Clin. Invest. 2019;129:1772-1778.
Not in our library10.1172/jci124283
45.
Mitochondria in Ischemic Stroke: New Insight and Implications · 2018
No notice
46.
Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22:391-397.
Not in our library10.1016/s0166-2236(99)01401-0
47.
Zhu J, et al. Up-regulation of GluN2A-containing NMDA receptor protects cultured cortical neuron cells from oxidative stress. Heliyon. 2018;4:e00976.
Not in our library10.1016/j.heliyon.2018.e00976
48.
Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem. 1984;43:1369-1374.
Not in our library10.1111/j.1471-4159.1984.tb05396.x
49.
Joyal JL, et al. Communication - Calmodulin activates phosphatidylinositol 3-kinase. J. Biol. Chem. 1997;272:28183-28186.
Not in our library10.1074/jbc.272.45.28183
50.
Alessi DR, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Curr. Biol. 1997;7:261-269.
Not in our library10.1016/s0960-9822(06)00122-9
51.
Zhang FX, Rubin R, Rooney TA. N-methyl-D-aspartate inhibits apoptosis through activation of phosphatidylinositol 3-kinase in cerebellar granule neurons - A role for insulin receptor substrate-1 in the neurotrophic action of N-methyl-D-aspartate and its inhibition by ethanol. J. Biol. Chem. 1998;273:26596-26602.
Not in our library10.1074/jbc.273.41.26596
52.
Jo H, et al. Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death. Proc. Natl Acad. Sci. USA. 2012;109:10581-10586.
Not in our library10.1073/pnas.1202810109
53.
Soriano FX, et al. Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. J. Neurosci. 2006;26:4509-4518.
Not in our library10.1523/jneurosci.0455-06.2006
54.
Yamaguchi A, et al. Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53. J. Biol. Chem. 2001;276:5256-5264.
Not in our library10.1074/jbc.m008552200
55.
Endo H, et al. Activation of the Akt/GSK3 beta signaling pathway mediates survival of vulnerable hippocampal neurons after transient global cerebral ischemia in rats. J. Cereb. Blood Flow. Metab. 2006;26:1479-1489.
Not in our library10.1038/sj.jcbfm.9600303
56.
Kawano T, et al. Neuroprotective effect of sodium orthovanadate on delayed neuronal death after transient forebrain ischemia in gerbil hippocampus. J. Cereb. Blood Flow. Metab. 2001;21:1268-1280.
Not in our library10.1097/00004647-200111000-00003
57.
Noshita N, et al. Copper-zinc superoxide dismutase affects Akt activation after transient focal cerebral ischemia in mice. Stroke. 2003;34:1513-1518.
Not in our library10.1161/01.str.0000072986.46924.f4
58.
Noshita N, Lewen A, Sugawara T, Chan PH. Evidence of phosphorylation of Akt and neuronal survival after transient focal cerebral ischemia in mice. J. Cereb. Blood Flow. Metab. 2001;21:1442-1450.
Not in our library10.1097/00004647-200112000-00009
59.
Yano S, et al. Activation of Akt/protein kinase B contributes to induction of ischemic tolerance in the CA1 subfield of gerbil hippocampus. J. Cereb. Blood Flow. Metab. 2001;21:351-360.
Not in our library10.1097/00004647-200104000-00004
60.
Downward J, How BAD. phosphorylation is good for survival. Nat. Cell Biol. 1999;1:E33-E35.
Not in our library10.1038/10026
61.
Kim AH, et al. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol. Cell. Biol. 2001;21:893-901.
Not in our library10.1128/mcb.21.3.893-901.2001
62.
Wu GY, Deisseroth K, Tsien RW. Activity-dependent CREB phosphorylation: Convergence of a fast, sensitive calmodulin kinase pathway and a slow, less sensitive mitogen-activated protein kinase pathway. Proc. Natl Acad. Sci. USA. 2001;98:2808-2813.
Not in our library10.1073/pnas.051634198
63.
Impey S, et al. Phosphorylation of CBP mediates transcriptional activation by neural activity and CaM kinase IV. Neuron. 2002;34:235-244.
Not in our library10.1016/s0896-6273(02)00654-2
64.
Favaron M, et al. NMDA-stimulated expression of BDNF mRNA in cultured cerebellar granule neurones. Neuroreport. 1993;4:1171-1174.
Not in our library10.1097/00001756-199307000-00033
65.
Hansen HH, et al. Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain. Neurobiol. Dis. 2004;16:440-453.
Not in our library10.1016/j.nbd.2004.03.013
66.
Shieh PB, et al. Identification of a signaling pathway involved in calcium regulation of BDNF expression. Neuron. 1998;20:727-740.
Not in our library10.1016/s0896-6273(00)81011-9
67.
Tao X, et al. Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron. 1998;20:709-726.
Not in our library10.1016/s0896-6273(00)81010-7
68.
Ghosh A, Carnahan J, Greenberg ME. Requirement for BDNF in activity-dependent survival of cortical neurons. Science. 1994;263:1618-1623.
Not in our library10.1126/science.7907431
69.
Zafra F, Castren E, Thoenen H, Lindholm D. Interplay between glutamate and gamma-aminobutyric acid transmitter systems in the physiological regulation of brain-derived neurotrophic factor and nerve growth factor synthesis in hippocampal neurons. Proc. Natl Acad. Sci. USA. 1991;88:10037-10041.
Not in our library10.1073/pnas.88.22.10037
70.
Chen Q, et al. Differential roles of NR2A- and NR2B-containing NMDA receptors in activity-dependent brain-derived neurotrophic factor gene regulation and limbic epileptogenesis. J. Neurosci. 2007;27:542-552.
Not in our library10.1523/jneurosci.3607-06.2007
71.
Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 2002;5:405-414.
Not in our library10.1038/nn835
72.
Comelli MC, et al. Photochemical stroke and brain-derived neurotrophic factor (BDNF) mRNA expression. Neuroreport. 1992;3:473-476.
Not in our library10.1097/00001756-199206000-00004
73.
Chen M, et al. Differential roles of NMDA Receptor Subtypes In Ischemic Neuronal Cell Death And Ischemic Tolerance. Stroke. 2008;39:3042-3048.
Not in our library10.1161/strokeaha.108.521898
74.
Ning K, et al. Dual neuroprotective signaling mediated by downregulating two distinct phosphatase activities of PTEN. J. Neurosci. 2004;24:4052-4060.
Not in our library10.1523/jneurosci.5449-03.2004
75.
Zhang S, et al. Critical role of increased PTEN nuclear translocation in excitotoxic and ischemic neuronal injuries. J. Neurosci. 2013;33:7997-8008.
Not in our library10.1523/jneurosci.5661-12.2013
76.
Kyrylenko S, Roschier M, Korhonen P, Salminen A. Regulation of PTEN expression in neuronal apoptosis. Mol. Brain Res. 1999;73:198-202.
Not in our library10.1016/s0169-328x(99)00259-4
77.
Deiss LP, et al. Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev. 1995;9:15-30.
Not in our library10.1101/gad.9.1.15
78.
Kissil JL, et al. DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene. Oncogene. 1997;15:403-407.
Not in our library10.1038/sj.onc.1201172
79.
Marshall J, et al. Calcium channel and NMDA receptor activities differentially regulate nuclear C/EBP beta levels to control neuronal survival. Neuron. 2003;39:625-639.
Not in our library10.1016/s0896-6273(03)00496-3
80.
Duval X, et al. Effect of early cerebral magnetic resonance imaging on clinical decisions in infective endocarditis: a prospective study. Ann. Intern. Med. 2010;152:497-504.
Not in our library10.7326/0003-4819-152-8-201004200-00006
81.
Shamloo M, et al. Death-associated protein kinase is activated by dephosphorylation in response to cerebral ischemia. J. Biol. Chem. 2005;280:42290-42299.
Not in our library10.1074/jbc.m505804200
82.
Chen CH, et al. Bidirectional signals transduced by DAPK-ERK interaction promote the apoptotic effect of DAPK. EMBO J. 2005;24:294-304.
Not in our library10.1038/sj.emboj.7600510
83.
Garthwaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature. 1988;336:385-388.
Not in our library10.1038/336385a0
84.
Brenman JE, et al. Cloning and characterization of postsynaptic density 93, a nitric oxide synthase interacting protein. J. Neurosci. 1996;16:7407-7415.
Not in our library10.1523/jneurosci.16-23-07407.1996
85.
Kornau H-C, Schenker LT, Kennedy MB, Seeburg PH. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science. 1995;269:1737-1740.
Not in our library10.1126/science.7569905
86.
Muller BM, et al. SAP102, a novel postsynaptic protein that interacts with NMDA receptor complexes in vivo. Neuron. 1996;17:255-265.
Not in our library10.1016/s0896-6273(00)80157-9
87.
Sattler R, et al. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95. protein Sci. 1999;284:1845-1848.
Not in our library10.1126/science.284.5421.1845
88.
Christopherson KS, Hillier BJ, Lim WA, Bredt DS. PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J. Biol. Chem. 1999;274:27467-27473.
Not in our library10.1074/jbc.274.39.27467
89.
Huang Z, et al. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science. 1994;265:1883-1885.
Not in our library10.1126/science.7522345
90.
Zhou L, et al. Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nat. Med. 2010;16:1439-U1123.
Not in our library10.1038/nm.2245
91.
Liu X, et al. Induction of apoptotic program in cell-free extracts: requirement for dATP and Cytochrome c. Cell. 1996;86:147-157.
Not in our library10.1016/s0092-8674(00)80085-9
92.
Murphy AN, Fiskum G, Flint Beal M. Mitochondria in neurodegeneration: Bioenergetic function in cell life and death. J. Cereb. Blood Flow. Metab. 1999;19:231-245.
Not in our library10.1097/00004647-199903000-00001
93.
Hofmeijer J, van Putten MJAM. Ischemic cerebral damage an appraisal of synaptic failure. Stroke. 2012;43:607-615.
Not in our library10.1161/strokeaha.111.632943
94.
Lee JM, Grabb MC, Zipfel GJ, Choi DW. Brain tissue responses to ischemia. J. Clin. Invest. 2000;106:723-731.
Not in our library10.1172/jci11003
95.
Dharmasaroja PA. Fluid intake related to brain edema in acute middle cerebral artery infarction. Transl. Stroke Res. 2016;7:49-53.
Not in our library10.1007/s12975-015-0439-1
96.
Huang Y, Li W, Su Z-Y, Kong A-NT. The complexity of the Nrf2 pathway: beyond the antioxidant response. J. Nutr. Biochem. 2015;26:1401-1413.
Not in our library10.1016/j.jnutbio.2015.08.001
97.
Xu J, et al. Luteolin provides neuroprotection in models of traumatic brain injury via the Nrf2-ARE pathway. Free Radic. Biol. Med. 2014;71:186-195.
Not in our library10.1016/j.freeradbiomed.2014.03.009
98.
Buendia I, et al. Nrf2-ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases. Pharmacol. Ther. 2016;157:84-104.
Not in our library10.1016/j.pharmthera.2015.11.003
99.
Schinzel AC, et al. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc. Natl Acad. Sci. USA. 2005;102:12005-12010.
Not in our library10.1073/pnas.0505294102
100.
Nakagawa T, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 2005;434:652-658.
Not in our library10.1038/nature03317
101.
Baines CP, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature. 2005;434:658-662.
Not in our library10.1038/nature03434
102.
Lutz J, Thuermel K, Heemann U. Anti-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation. J. Inflamm. 2010;7:27.
Not in our library10.1186/1476-9255-7-27
103.
Hou Y, Wang J, Feng J. The neuroprotective effects of curcumin are associated with the regulation of the reciprocal function between autophagy and HIF-1α in cerebral ischemia-reperfusion injury. Drug Des., Dev. Ther. 2019;13:1135-1144.
Not in our library10.2147/dddt.s194182
104.
Metformin attenuates blood-brain barrier disruption in mice following middle cerebral artery occlusion · 2014
No notice
105.
Dai SH, et al. Sirt3 confers protection against neuronal ischemia by inducing autophagy: Involvement of the AMPK-mTOR pathway. Free Radic. Biol. Med. 2017;108:345-353.
Not in our library10.1016/j.freeradbiomed.2017.04.005
106.
Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology. 2009;24:97-106.
Not in our library10.1152/physiol.00045.2008
107.
Ziello JE, Jovin IS, Huang Y. Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J. Biol. Med. 2007;80:51-60.
Not in our library
108.
Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3:177-185.
Not in our library10.1016/j.cmet.2006.02.002
109.
Hu CJ, et al. Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1 alpha) and HIF-2 alpha in stem cells. Mol. Cell. Biol. 2006;26:3514-3526.
Not in our library10.1128/mcb.26.9.3514-3526.2006
110.
Guo S, Miyake M, Liu KJ, Shi H. Specific inhibition of hypoxia inducible factor 1 exaggerates cell injury induced by in vitro ischemia through deteriorating cellular redox environment. J. Neurochem. 2009;108:1309-1321.
Not in our library10.1111/j.1471-4159.2009.05877.x
111.
Itoh K, et al. Emerging functional cross-talk between the Keap1-Nrf2 system and mitochondria. J. Clin. Biochem. Nutr. 2015;56:91-97.
Not in our library10.3164/jcbn.14-134
112.
Malhotra D, et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 2010;38:5718-5734.
Not in our library10.1093/nar/gkq212
113.
The emerging role of Nrf2 in mitochondrial function · 2015
No notice
114.
Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration · 2013
No notice
115.
Xu Y-P, Han F, Tan J. Edaravone protects the retina against ischemia/reperfusion-induced oxidative injury through the PI3K/Akt/Nrf2 pathway. Mol. Med. Report. 2017;16:9210-9216.
Not in our library10.3892/mmr.2017.7739
116.
Kitagawa H, et al. Immunoreactive Akt, PI3-K and ERK protein kinase expression in ischemic rat brain. Neurosci. Lett. 1999;274:45-48.
Not in our library10.1016/s0304-3940(99)00676-x
117.
Cen J, et al. Polyamine analogue QMA attenuated ischemic injury in MCAO rats via ERK and Akt activated Nrf2/HO-1 signaling pathway. Eur. J. Pharmacol. 2019;844:165-174.
Not in our library10.1016/j.ejphar.2018.12.015
118.
Chang C-Y, et al. Tetramethylpyrazine inhibits neutrophil activation following permanent cerebral ischemia in rats. Biochem. Biophys. Res. Commun. 2015;463:421-427.
Not in our library10.1016/j.bbrc.2015.05.088
119.
Innamorato NG, et al. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J. Immunol. 2008;181:680-689.
Not in our library10.4049/jimmunol.181.1.680
120.
Kim GS, et al. Release of mitochondrial apoptogenic factors and cell death are mediated by CK2 and NADPH oxidase. J. Cereb. Blood Flow. Metab. 2012;32:720-730.
Not in our library10.1038/jcbfm.2011.176
121.
Diekmann D, et al. Interaction of Rac with p67-phox and regulation of phagocytic NADPH oxidase activity. Sci. (Wash. D. C). 1994;265:531-533.
Not in our library10.1126/science.8036496
122.
Sarfstein R, et al. Dual role of Rac in the assembly of NADPH oxidase, tethering to the membrane and activation of p67(phox) - A study based on mutagenesis of p67(phox)-Rac1 chimeras. J. Biol. Chem. 2004;279:16007-16016.
Not in our library10.1074/jbc.m312394200
123.
Zimmer S, et al. Inhibition of Rac1 GTPase decreases vascular oxidative stress, improves endothelial function, and attenuates atherosclerosis development in mice. Front. Cardiovasc. Med. 2021;8:680775.
Not in our library10.3389/fcvm.2021.680775
124.
Mandal T, et al. Reduced phosphorylation of Stat3 at Ser-727 mediated by casein kinase 2-Protein phosphatase 2A enhances Stat3 Tyr-705 induced tumorigenic potential of glioma cells. Cell. Signal. 2014;26:1725-1734.
Not in our library10.1016/j.cellsig.2014.04.003
125.
Jung JE, Kim GS, Chan PH. Neuroprotection by Interleukin-6 is mediated by signal transducer and activator of Transcription 3 and antioxidative signaling in ischemic stroke. Stroke. 2011;42:3574-U3371.
Not in our library10.1161/strokeaha.111.626648
126.
Chao CC, Ma YL, Lee EHY. Brain-derived neurotrophic factor enhances Bcl-xL expression through protein kinase Casein Kinase 2-activated and nuclear factor Kappa B-mediated pathway in Rat Hippocampus. Brain Pathol. 2011;21:150-162.
Not in our library10.1111/j.1750-3639.2010.00431.x
127.
Afonyushkin T, Oskolkova OV, Binder BR, Bochkov VN. Involvement of CK2 in activation of electrophilic genes in endothelial cells by oxidized phospholipids. J. Lipid Res. 2011;52:98-103.
Not in our library10.1194/jlr.m009480
128.
Baltan S, et al. CK2 inhibition protects white matter from ischemic injury. Neurosci. Lett. 2018;687:37-42.
Not in our library10.1016/j.neulet.2018.08.021
129.
Bastian C, et al. CK2 inhibition confers functional protection to young and aging axons against ischemia by differentially regulating the CDK5 and AKT signaling pathways. Neurobiol. Dis. 2019;126:47-61.
Not in our library10.1016/j.nbd.2018.05.011
130.
Meyer DA, et al. Ischemic stroke injury is mediated by Aberrant Cdk5. J. Neurosci. 2014;34:8259-8267.
Not in our library10.1523/jneurosci.4368-13.2014
131.
Tan X, et al. The inhibition of CDK5 activity after hypoxia/ischemia injury reduces infarct size and promotes functional recovery in neonatal rats. Neuroscience. 2015;290:552-560.
Not in our library10.1016/j.neuroscience.2015.01.054
132.
Palikaras K, Tavernarakis N. Mitochondrial homeostasis: The interplay between mitophagy and mitochondrial biogenesis. Exp. Gerontol. 2014;56:182-188.
Not in our library10.1016/j.exger.2014.01.021
133.
Feng J, et al. Inhibition of peroxynitrite-induced mitophagy activation attenuates cerebral ischemia-reperfusion injury. Mol. Neurobiol. 2018;55:6369-6386.
Not in our library10.1007/s12035-017-0859-x
134.
Di Sante G, et al. Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays Park2 translocation to mitochondria. Am. J. Pathol. 2015;185:266-279.
Not in our library10.1016/j.ajpath.2014.09.014
135.
Gustafsson AB. Bnip3 as a dual regulator of mitochondrial turnover and cell death in the myocardium. Pediatr. Cardiol. 2011;32:267-274.
Not in our library10.1007/s00246-010-9876-5
136.
Cui T, et al. Silencing of PINK1 induces mitophagy via mitochondrial permeability transition in dopaminergic MN9D cells. Brain Res. 2011;1394:1-13.
Not in our library10.1016/j.brainres.2011.01.035
137.
Clearance of damaged mitochondria via mitophagy is important to the protective effect of ischemic preconditioning in kidneys · 2019
No notice
138.
Fan P, et al. Molecular regulation mechanisms and interactions between reactive oxygen species and mitophagy. DNA Cell Biol. 2019;38:10-22.
Not in our library10.1089/dna.2018.4348
139.
Bursch W, et al. Active cell death induced by the anti-estrogens tamoxifen and ICI 164384 in human mammary carcinoma cells (MCF-7) in culture: The role of autophagy. Carcinogenesis. 1996;17:1595-1607.
Not in our library10.1093/carcin/17.8.1595
140.
Clarke PG. Developmental cell death: morphological diversity and multiple mechanisms. Anat. Embryol. 1990;181:195-213.
Not in our library10.1007/bf00174615
141.
Majno G, Joris I. Apoptosis, oncosis, and necrosis: An overview of cell death. Am. J. Pathol. 1995;146:3-15.
Not in our library
142.
He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 2009;43:67-93.
Not in our library10.1146/annurev-genet-102808-114910
143.
Parzych KR, Klionsky DJ. An overview of autophagy: morphology, mechanism, and regulation. Antioxid. Redox Signal. 2014;20:460-473.
Not in our library10.1089/ars.2013.5371
144.
Balin B, Abrams JT, Schrogie J. Toward a unifying hypothesis in the development of Alzheimer’s disease. CNS Neurosci. Ther. 2011;17:587-589.
Not in our library10.1111/j.1755-5949.2011.00269.x
145.
Berezniuk I, Fricker LD. A defect in cytosolic carboxypeptidase 1 (Nna1) causes autophagy in Purkinje cell degeneration mouse brain. Autophagy. 2010;6:558-559.
Not in our library10.4161/auto.6.4.11813
146.
Medeiros R, Baglietto-Vargas D, LaFerla FM. The role of Tau in Alzheimer’s disease and related disorders. CNS Neurosci. Ther. 2011;17:514-524.
Not in our library10.1111/j.1755-5949.2010.00177.x
147.
Chu CT. Eaten alive - Autophagy and neuronal cell death after hypoxia-ischemia. Am. J. Pathol. 2008;172:284-287.
Not in our library10.2353/ajpath.2008.071064
148.
Wang X, et al. An updated review of autophagy in ischemic stroke: From mechanisms to therapies. Exp. Neurol. 2021;340:113684.
Not in our library10.1016/j.expneurol.2021.113684
149.
Kim YC, Guan K-L. mTOR: a pharmacologic target for autophagy regulation. J. Clin. Investig. 2015;125:25-32.
Not in our library10.1172/jci73939
150.
Role of mTORC1 Controlling Proteostasis after Brain Ischemia · 2018
Not checked
151.
Fang W, et al. CCR2-dependent monocytes/macrophages exacerbate acute brain injury but promote functional recovery after ischemic stroke in mice. Theranostics. 2018;8:3530-3543.
Not in our library10.7150/thno.24475
152.
Microglial cell loss after ischemic stroke favors brain neutrophil accumulation · 2018
No notice
153.
Guo Y-Q, et al. Expression of CCL2 and CCR2 in the hippocampus and the interventional roles of propofol in rat cerebral ischemia/reperfusion. Exp. Ther. Med. 2014;8:657-661.
Not in our library10.3892/etm.2014.1757
154.
Wei HP, et al. cPKC gamma-modulated autophagy in neurons alleviates ischemic injury in brain of mice with ischemic stroke through Akt-mTOR pathway. Transl. Stroke Res. 2016;7:497-511.
Not in our library10.1007/s12975-016-0484-4
155.
Carloni S, Buonocore G, Balduini W. Protective role of autophagy in neonatal hypoxia-ischemia induced brain injury. Neurobiol. Dis. 2008;32:329-339.
Not in our library10.1016/j.nbd.2008.07.022
156.
Wang MY, et al. Homocysteine enhances neural stem cell autophagy in in vivo and in vitro model of ischemic stroke. Cell Death Dis. 2019;10:561.
Not in our library10.1038/s41419-019-1798-4
157.
Jiang T, et al. Acute metformin preconditioning confers neuroprotection against focal cerebral ischaemia by pre-activation of AMPK-dependent autophagy. Br. J. Pharmacol. 2014;171:3146-3157.
Not in our library10.1111/bph.12655
158.
Yu ZH, et al. Neuroprotective effects of Tongxinluo on focal cerebral ischemia and reperfusion injury in rats associated with the activation of the MEK1/2/ERK1/2/p90RSK signaling pathway. Brain Res. 2018;1685:9-18.
Not in our library10.1016/j.brainres.2018.01.036
159.
Bootman MD, et al. The regulation of autophagy by calcium signals: Do we have a consensus? Cell Calcium. 2018;70:32-46.
Not in our library10.1016/j.ceca.2017.08.005
160.
Morselli E, et al. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle. 2008;7:3056-3061.
Not in our library10.4161/cc.7.19.6751
161.
Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys. Acta. 2007;1773:1358-1375.
Not in our library10.1016/j.bbamcr.2007.03.010
162.
Kalra, P., Khan, H., Kaur, A. & Singh, T. G. Mechanistic insight on autophagy modulated molecular pathways in cerebral ischemic injury: from preclinical to clinical perspective. Neurochem. Res., (2022).
Not in our library10.1007/s11064-021-03500-0
163.
Cui DR, et al. Propofol prevents cerebral ischemia-triggered autophagy activation and cell death in the rat hippocampus through the NF-kappaB/p53 signaling pathway. Neuroscience. 2013;246:117-132.
Not in our library10.1016/j.neuroscience.2013.04.054
164.
Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481-487.
Not in our library10.1038/nature21029
165.
Xu D, et al. Orexin-A protects against cerebral ischemia-reperfusion injury by inhibiting excessive autophagy through OX1R-mediated MAPK/ERK/mTOR pathway. Cell. Signal. 2021;79:109839.
Not in our library10.1016/j.cellsig.2020.109839
166.
Rami A. Upregulation of Beclin 1 in the ischemic penumbra. Autophagy. 2008;4:227-229.
Not in our library10.4161/auto.5339
167.
Qi Z, et al. Bcl-2 phosphorylation triggers autophagy switch and reduces mitochondrial damage in limb remote ischemic conditioned rats after ischemic stroke. Transl. Stroke Res. 2015;6:198-206.
Not in our library10.1007/s12975-015-0393-y
168.
Xu F, et al. Peroxisome proliferator-activated receptor-gamma agonist 15d-prostaglandin J2 mediates neuronal autophagy after cerebral ischemia-reperfusion injury. PLoS One. 2013;8:e55080.
Not in our library10.1371/journal.pone.0055080
169.
Qi J, et al. Rab7b overexpression-ameliorated ischemic brain damage following tMCAO involves suppression of TLR4 and NF-kappaB p65. J. Mol. Neurosci. 2019;68:163-170.
Not in our library10.1007/s12031-019-01295-y
170.
Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics · 1972
No notice
171.
Uzdensky AB. Apoptosis regulation in the penumbra after ischemic stroke: expression of pro- and antiapoptotic proteins. Apoptosis. 2019;24:687-702.
Not in our library10.1007/s10495-019-01556-6
172.
Benn SC, Woolf CJ. Adult neuron survival strategies-slamming on the brakes. Nat. Rev. Neurosci. 2004;5:686-700.
Not in our library10.1038/nrn1477
173.
Velier JJ, et al. Caspase-8 and caspase-3 are expressed by different populations of cortical neurons undergoing delayed cell death after focal stroke in the rat. J. Neurosci. 1999;19:5932-5941.
Not in our library10.1523/jneurosci.19-14-05932.1999
174.
Love S. Apoptosis and brain ischaemia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2003;27:267-282.
Not in our library10.1016/s0278-5846(03)00022-8
175.
Plesnila N, et al. BID mediates neuronal cell death after oxygen/ glucose deprivation and focal cerebral ischemia. Proc. Natl Acad. Sci. USA. 2001;98:15318-15323.
Not in our library10.1073/pnas.261323298
176.
Yin XM, et al. Bid-mediated mitochondrial pathway is critical to ischemic neuronal apoptosis and focal cerebral ischemia. J. Biol. Chem. 2002;277:42074-42081.
Not in our library10.1074/jbc.m204991200
177.
Sarmah, D. et al. Mitochondrial Dysfunction in Stroke: Implications of Stem Cell Therapy. Transl. Stroke Res., (2018).
Not in our library10.1007/s12975-018-0642-y
178.
Sekerdag E, Solaroglu I, Gursoy-Ozdemir Y. Cell death mechanisms in stroke and novel molecular and cellular treatment options. Curr. Neuropharmacol. 2018;16:1396-1415.
Not in our library10.2174/1570159x16666180302115544
179.
Scheinberg P. Survival of the ischemic brain: a progress report. Circulation. 1979;60:1600-1605.
Not in our library10.1161/01.cir.60.7.1600
180.
Leng T, Shi Y, Xiong ZG, Sun D. Proton-sensitive cation channels and ion exchangers in ischemic brain injury: new therapeutic targets for stroke? Prog. Neurobiol. 2014;115:189-209.
Not in our library10.1016/j.pneurobio.2013.12.008
181.
Chamorro Á, Dirnagl U, Urra X, Planas AM. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol. 2016;15:869-881.
Not in our library10.1016/s1474-4422(16)00114-9
182.
Collingridge GL, Isaac JT, Wang YT. Receptor trafficking and synaptic plasticity. Nat. Rev. Neurosci. 2004;5:952-962.
Not in our library10.1038/nrn1556
183.
Vats K, et al. Inflammasomes in stroke: a triggering role for acid-sensing ion channels. Ann. N. Y. Acad. Sci. 2018;1431:14-24.
Not in our library10.1111/nyas.13852
184.
Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94:491-501.
Not in our library10.1016/s0092-8674(00)81590-1
185.
Bauer TM, Murphy E. Role of mitochondrial calcium and the permeability transition pore in regulating cell death. Circ. Res. 2020;126:280-293.
Not in our library10.1161/circresaha.119.316306
186.
Fricker M, et al. Neuronal cell death. Physiol. Rev. 2018;98:813-880.
Not in our library10.1152/physrev.00011.2017
187.
Hollville E, Romero SE, Deshmukh M. Apoptotic cell death regulation in neurons. FEBS J. 2019;286:3276-3298.
Not in our library10.1111/febs.14970
188.
Leker RR, Aharonowiz M, Greig NH, Ovadia H. The role of p53-induced apoptosis in cerebral ischemia: effects of the p53 inhibitor pifithrin alpha. Exp. Neurol. 2004;187:478-486.
Not in our library10.1016/j.expneurol.2004.01.030
189.
Culmsee C, Krieglstein J. Ischaemic brain damage after stroke: new insights into efficient therapeutic strategies. International Symposium on Neurodegeneration and Neuroprotection. EMBO Rep. 2007;8:129-133.
Not in our library10.1038/sj.embor.7400892
190.
Morrison RS, et al. p53-dependent cell death signaling in neurons. Neurochem. Res. 2003;28:15-27.
Not in our library10.1023/a:1021687810103
191.
Cregan SP, et al. p53 activation domain 1 is essential for PUMA upregulation and p53-mediated neuronal cell death. J. Neurosci. 2004;24:10003-10012.
Not in our library10.1523/jneurosci.2114-04.2004
192.
Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene. 2004;23:2797-2808.
Not in our library10.1038/sj.onc.1207532
193.
Balaganapathy P, et al. Interplay between Notch and p53 promotes neuronal cell death in ischemic stroke. J. Cereb. Blood Flow. Metab. 2018;38:1781-1795.
Not in our library10.1177/0271678x17715956
194.
Baik S-H, et al. Pin1 promotes neuronal death in stroke by stabilizing notch intracellular domain. Ann. Neurol. 2015;77:504-516.
Not in our library10.1002/ana.24347
195.
Arumugam TV, et al. Evidence that gamma-Secretase-mediated notch signaling induces neuronal cell death via the nuclear Factor-kappa B-Bcl-2-interacting mediator of cell death pathway in ischemic stroke. Mol. Pharmacol. 2011;80:23-31.
Not in our library10.1124/mol.111.071076
196.
Wei Z, et al. Notch activation enhances the microglia-mediated inflammatory response associated with focal cerebral ischemia. Stroke. 2011;42:2589-U2344.
Not in our library10.1161/strokeaha.111.614834
197.
Cheng Y-L, et al. Evidence that neuronal Notch-1 promotes JNK/c-Jun activation and cell death following ischemic stress. Brain Res. 2014;1586:193-202.
Not in our library10.1016/j.brainres.2014.08.054
198.
Evidence that collaboration between HIF-1α and Notch-1 promotes neuronal cell death in ischemic stroke · 2014
Not checked
199.
Deb P, Sharma S, Hassan KM. Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis. Pathophysiol.: Off. J. Int. Soc. Pathophysiol. 2010;17:197-218.
Not in our library10.1016/j.pathophys.2009.12.001
200.
Festjens N, Vanden Berghe T, Vandenabeele P. Necrosis, a well-orchestrated form of cell demise: Signalling cascades, important mediators and concomitant immune response. Biochimica Et. Biophysica Acta-Bioenerg. 2006;1757:1371-1387.
Not in our library10.1016/j.bbabio.2006.06.014
201.
Nuclear RIPK3 and MLKL contribute to cytosolic necrosome formation and necroptosis · 2018
No notice
202.
Vieira M, et al. Ischemic insults induce necroptotic cell death in hippocampal neurons through the up-regulation of endogenous RIP3. Neurobiol. Dis. 2014;68:26-36.
Not in our library10.1016/j.nbd.2014.04.002
203.
Sun L, et al. Mixed Lineage Kinase Domain-like Protein mediates necrosis signaling downstream of RIP3 Kinase. Cell. 2012;148:213-227.
Not in our library10.1016/j.cell.2011.11.031
204.
Vanden Berghe T, et al. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat. Rev. Mol. Cell Biol. 2014;15:134-146.
Not in our library10.1038/nrn3690
205.
Dondelinger Y, et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep. 2014;7:971-981.
Not in our library10.1016/j.celrep.2014.04.026
206.
Galluzzi L, Kepp O, Kroemer G. MLKL regulates necrotic plasma membrane permeabilization. Cell Res. 2014;24:139-140.
Not in our library10.1038/cr.2014.8
207.
Dong Z, et al. The possibility and molecular mechanisms of cell pyroptosis after cerebral ischemia. Neurosci. Bull. 2018;34:1131-1136.
Not in our library10.1007/s12264-018-0294-7
208.
Kono H, Kimura Y, Latz E. Inflammasome activation in response to dead cells and their metabolites. Curr. Opin. Immunol. 2014;30:91-98.
Not in our library10.1016/j.coi.2014.09.001
209.
Poh L, et al. Evidence that NLRC4 inflammasome mediates apoptotic and pyroptotic microglial death following ischemic stroke. Brain Behav. Immun. 2019;75:34-47.
Not in our library10.1016/j.bbi.2018.09.001
210.
Mechanisms of ferroptosis · 2016
No notice
211.
Tan SL, et al. The regulation of reactive oxygen species production during programmed cell death. J. Cell Biol. 1998;141:1423-1432.
Not in our library10.1083/jcb.141.6.1423
212.
Kenny EM, et al. Ferroptosis contributes to neuronal death and functional outcome after traumatic brain injury. Crit. Care Med. 2019;47:410-418.
Not in our library10.1097/ccm.0000000000003555
213.
Crosstalk between Oxidative Stress and Ferroptosis/Oxytosis in Ischemic Stroke: Possible Targets and Molecular Mechanisms · 2021
No notice
214.
Shichita T, et al. MAFB prevents excess inflammation after ischemic stroke by accelerating clearance of damage signals through MSR1. Nat. Med. 2017;23:723.
Not in our library10.1038/nm.4312
215.
Gadani SP, Walsh JT, Lukens JR, Kipnis J. Dealing with danger in the CNS: the response of the immune system to injury. Neuron. 2015;87:47-62.
Not in our library10.1016/j.neuron.2015.05.019
216.
Gelderblom M, et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke. 2009;40:1849-1857.
Not in our library10.1161/strokeaha.108.534503
217.
Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat. Med. 2011;17:796-808.
Not in our library10.1038/nm.2399
218.
Huang J, Upadhyay UM, Tamargo RJ. Inflammation in stroke and focal cerebral ischemia. Surg. Neurol. 2006;66:232-245.
Not in our library10.1016/j.surneu.2005.12.028
219.
Zhang RL, et al. The expression of P- and E-selectins in three models of middle cerebral artery occlusion. Brain Res. 1998;785:207-214.
Not in our library10.1016/s0006-8993(97)01343-7
220.
Functional morphology of the blood–brain barrier in health and disease · 2018
No notice
221.
Stanimirovic D, Satoh K. Inflammatory mediators of cerebral endothelium: A role in ischemic brain inflammation. Brain Pathol. 2000;10:113-126.
Not in our library10.1111/j.1750-3639.2000.tb00248.x
222.
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy · 2017
No notice
223.
Ishitsuka K, et al. Neurotrophin production in brain pericytes during hypoxia: A role of pericytes for neuroprotection. Microvasc. Res. 2012;83:352-359.
Not in our library10.1016/j.mvr.2012.02.009
224.
Badaut T, Lasbennes T, Magistretti PJ, Regli L. Aquaporins in brain: Distribution, physiology, and pathophysiology. J. Cereb. Blood Flow. Metab. 2002;22:367-378.
Not in our library10.1097/00004647-200204000-00001
225.
Badaut J, et al. Temporal and regional evolution of aquaporin-4 expression and magnetic resonance imaging in a rat pup model of neonatal stroke. Pediatr. Res. 2007;62:248-254.
Not in our library10.1203/pdr.0b013e3180db291b
226.
Post-stroke inflammation—target or tool for therapy? · 2018
No notice
227.
Lambertsen KL, et al. Microglia protect neurons against ischemia by synthesis of tumor necrosis factor. J. Neurosci. 2009;29:1319-1330.
Not in our library10.1523/jneurosci.5505-08.2009
228.
Clausen BH, et al. Cell therapy centered on IL-1Ra is neuroprotective in experimental stroke. Acta Neuropathol. 2016;131:775-791.
Not in our library10.1007/s00401-016-1541-5
229.
Kirchner S, et al. LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK/ERK pathway. J. Leukoc. Biol. 2004;75:324-331.
Not in our library10.1189/jlb.0703343
230.
Grell M, Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc. Natl Acad. Sci. USA. 1998;95:570-575.
Not in our library10.1073/pnas.95.2.570
231.
Grell M, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995;83:793-802.
Not in our library10.1016/0092-8674(95)90192-2
232.
Um JY, An NH, Kim HM. TNF-alpha and TNF-beta gene polyrnorphisms in cerebral infarction. J. Mol. Neurosci. 2003;21:167-171.
Not in our library10.1385/jmn:21:2:167
233.
Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. J. Cereb. Blood Flow. Metab. 2012;32:1677-1698.
Not in our library10.1038/jcbfm.2012.88
234.
Taoufik E, et al. TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proc. Natl Acad. Sci. USA. 2008;105:6185-6190.
Not in our library10.1073/pnas.0801447105
235.
Madsen PM, et al. Genetic ablation of soluble tumor necrosis factor with preservation of membrane tumor necrosis factor is associated with neuroprotection after focal cerebral ischemia. J. Cereb. Blood Flow. Metab. 2016;36:1553-1569.
Not in our library10.1177/0271678x15610339
236.
Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720-3732.
Not in our library10.1182/blood-2010-07-273417
237.
Zou L, et al. The association between three promoter polymorphisms of IL-1 and stroke: A meta-analysis. Gene. 2015;567:36-44.
Not in our library10.1016/j.gene.2015.04.054
238.
Bis JC, et al. Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke. Atherosclerosis. 2008;198:166-173.
Not in our library10.1016/j.atherosclerosis.2007.09.031
239.
Thornton P, et al. Platelet interleukin-1 alpha drives cerebrovascular inflammation. Blood. 2010;115:3632-3639.
Not in our library10.1182/blood-2009-11-252643
240.
Davies CA, et al. The progression and topographic distribution of interleukin-1 beta expression after permanent middle cerebral artery occlusion in the rat. J. Cereb. Blood Flow. Metab. 1999;19:87-98.
Not in our library10.1097/00004647-199901000-00010
241.
Spulber S, Bartfai T, Schultzberg M. IL-1/IL-1ra balance in the brain revisited - Evidence from transgenic mouse models. Brain Behav. Immun. 2009;23:573-579.
Not in our library10.1016/j.bbi.2009.02.015
242.
Sobowale OA, et al. Interleukin-1 in stroke from bench to bedside. Stroke. 2016;47:2160-2167.
Not in our library10.1161/strokeaha.115.010001
243.
Boutin H, et al. Role of IL-1 alpha and IL-1 beta in ischemic brain damage. J. Neurosci. 2001;21:5528-5534.
Not in our library10.1523/jneurosci.21-15-05528.2001
244.
McColl BW, Rothwell NJ, Allan SM. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J. Neurosci. 2007;27:4403-4412.
Not in our library10.1523/jneurosci.5376-06.2007
245.
Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int. J. Biol. Sci. 2012;8:1254-1266.
Not in our library10.7150/ijbs.4679
246.
Gronhoj MH, et al. Beneficial potential of intravenously administered IL-6 in improving outcome after murine experimental stroke. Brain Behav. Immun. 2017;65:296-311.
Not in our library10.1016/j.bbi.2017.05.019
247.
Riethmueller S, et al. Cleavage site localization differentially controls interleukin-6 receptor proteolysis by ADAM10 and ADAM17. Sci. Rep. 2016;6:25550.
Not in our library10.1038/srep25550
248.
Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: A highly regulated and dynamic system. Cytokine. 2014;70:11-20.
Not in our library10.1016/j.cyto.2014.05.024
249.
Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochimica Et. Biophysica Acta-Mol. Cell Res. 2016;1863:1218-1227.
Not in our library10.1016/j.bbamcr.2016.03.018
250.
Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochimica Et. Biophysica Acta-Mol. Cell Res. 2011;1813:878-888.
Not in our library10.1016/j.bbamcr.2011.01.034
251.
Smith CJ, et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. 2004;4:2.
Not in our library10.1186/1471-2377-4-2
252.
Selected acute phase CSF factors in ischemic stroke: findings and prognostic value · 2011
Not checked
253.
Singh N, et al. The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial. J. Neuroinflammation. 2014;11:1.
Not in our library10.1186/1742-2094-11-1
254.
Meng C, et al. Inhibition of interleukin-6 abolishes the promoting effects of pair housing on post-stroke neurogenesis. Neuroscience. 2015;307:160-170.
Not in our library10.1016/j.neuroscience.2015.08.055
255.
Sabat R, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010;21:331-344.
Not in our library10.1016/j.cytogfr.2010.09.002
256.
Xu L, et al. Astrocyte targeted overexpression of Hsp72 or SOD2 reduces neuronal vulnerability to forebrain ischemia. Glia. 2010;58:1042-1049.
Not in our library10.1002/glia.20985
257.
de Bilbao F, et al. In vivo over-expression of interleukin-10 increases resistance to focal brain ischemia in mice. J. Neurochem. 2009;110:12-22.
Not in our library10.1111/j.1471-4159.2009.06098.x
258.
Perez-de Puig I, et al. IL-10 deficiency exacerbates the brain inflammatory response to permanent ischemia without preventing resolution of the lesion. J. Cereb. Blood Flow. Metab. 2013;33:1955-1966.
Not in our library10.1038/jcbfm.2013.155
259.
Vila N, et al. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke. 2003;34:671-675.
Not in our library10.1161/01.str.0000057976.53301.69
260.
Protti GG, Gagliardi RJ, Forte WCN, Sprovieri SRS. Interleukin-10 may protect against progressing injury during the acute phase of ischemic stroke. Arq. Neuropsiquiatr. 2013;71:846-851.
Not in our library10.1590/0004-282x20130168
261.
Mennicken F, Maki R, de Souza EB, Quirion R. Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning. Trends Pharmacol. Sci. 1999;20:73-78.
Not in our library10.1016/s0165-6147(99)01308-5
262.
Hughes PM, et al. Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. J. Cereb. Blood Flow. Metab. 2002;22:308-317.
Not in our library10.1097/00004647-200203000-00008
263.
Dimitrijevic OB, Stamatovic SM, Keep RF, Andjelkovic AV. Absence of the chemokine receptor CCR2 protects against cerebral Ischemia/reperfusion injury in mice. Stroke. 2007;38:1345-1353.
Not in our library10.1161/01.str.0000259709.16654.8f
264.
Chen Y, et al. Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J. Cereb. Blood Flow. Metab. 2003;23:748-755.
Not in our library10.1097/01.wcb.0000071885.63724.20
265.
Kim JS, et al. Expression of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 after focal cerebral ischemia in the rat. J. Neuroimmunol. 1995;56:127-134.
Not in our library10.1016/0165-5728(94)00138-e
266.
Takami S, et al. Chemokine receptor antagonist peptide, viral MIP-II, protects the brain against focal cerebral ischemia in mice. J. Cereb. Blood Flow. Metab. 2001;21:1430-1435.
Not in our library10.1097/00004647-200112000-00007
267.
Terao S, et al. Blood cell-derived RANTES mediates cerebral microvascular dysfunction, inflammation, and tissue injury after focal ischemia-reperfusion. Stroke. 2008;39:2560-2570.
Not in our library10.1161/strokeaha.107.513150
268.
Montecucco F, et al. Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. Stroke. 2010;41:1394-1404.
Not in our library10.1161/strokeaha.110.578369
269.
Chen C, et al. Chemokines play complex roles in cerebral ischemia. Neurochem. Int. 2018;112:146-158.
Not in our library10.1016/j.neuint.2017.06.008
270.
Glezer I, Simard AR, Rivest S. Neuroprotective role of the innate immune system by microglia. Neuroscience. 2007;147:867-883.
Not in our library10.1016/j.neuroscience.2007.02.055
271.
McGettrick AF, O’Neill LAJ. Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. Br. J. Haematol. 2007;139:185-193.
Not in our library10.1111/j.1365-2141.2007.06802.x
272.
Arancibia SA, et al. Toll-like receptors are key participants in innate immune responses. Biol. Res. 2007;40:97-112.
Not in our library10.4067/s0716-97602007000200001
273.
Manicassamy S, Pulendran B. Modulation of adaptive immunity with Toll-like receptors. Semin. Immunol. 2009;21:185-193.
Not in our library10.1016/j.smim.2009.05.005
274.
TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion · 2010
No notice
275.
Chaturvedi A, Pierce SK. How location governs toll-like receptor signaling. Traffic. 2009;10:621-628.
Not in our library10.1111/j.1600-0854.2009.00899.x
276.
Beyond the Brain: The Systemic Pathophysiological Response to Acute Ischemic Stroke · 2020
Not checked
277.
Florez-Alvarez L, Ruiz-Perez L, Taborda N, Hernandez JC. Toll-like receptors as a therapeutic target in cancer, infections and inflammatory diseases. Immunotherapy. 2020;12:311-322.
Not in our library10.2217/imt-2019-0096
278.
Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010;11:373-384.
Not in our library10.1038/ni.1863
279.
Brien JD, et al. Interferon Regulatory Factor-1 (IRF-1) shapes both innate and CD8(+) T cell immune responses against West Nile virus infection. Plos Pathog. 2011;7:e1002230.
Not in our library10.1371/journal.ppat.1002230
280.
Takahashi H, Nishibori M. Current status and future prospects in HMGB1 and receptor researches. Nihon Rinsho. 2016;74:703-711.
Not in our library
281.
Marsh B, et al. Systemic Lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: a critical role for IRF3. J. Neurosci. 2009;29:9839-9849.
Not in our library10.1523/jneurosci.2496-09.2009
282.
Gesuete R, Kohama SG, Stenzel-Poore MP. Toll-like receptors and ischemic brain injury. J. Neuropathol. Exp. Neurol. 2014;73:378-386.
Not in our library10.1097/nen.0000000000000068
283.
LPS preconditioning redirects TLR signaling following stroke: TRIF-IRF3 plays a seminal role in mediating tolerance to ischemic injury · 2011
No notice
284.
Kurita N, et al. Metabolic endotoxemia promotes neuroinflammation after focal cerebral ischemia. J. Cereb. Blood Flow. Metab. 2020;40:2505-2520.
Not in our library10.1177/0271678x19899577
285.
Singh V, Roth S, Veltkamp R, Liesz A. HMGB1 as a key mediator of immune mechanisms in ischemic stroke. Antioxid. Redox Signal. 2016;24:635-651.
Not in our library10.1089/ars.2015.6397
286.
Magna M, Pisetsky DS. The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Mol. Med. 2014;20:138-146.
Not in our library10.2119/molmed.2013.00164
287.
Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochimica Et. Biophysica Acta-Gene Regul. Mech. 2010;1799:149-156.
Not in our library10.1016/j.bbagrm.2009.11.019
288.
Yang H, Wang HC, Czura CJ, Tracey KJ. The cytokine activity of HMGB1. J. Leukoc. Biol. 2005;78:1-8.
Not in our library10.1189/jlb.1104648
289.
Qiu J, et al. Early release of HMGB-1 from neurons after the onset of brain ischemia. J. Cereb. Blood Flow. Metab. 2008;28:927-938.
Not in our library10.1038/sj.jcbfm.9600582
290.
Deng W, et al. Transcriptomic characterization of microglia activation in a rat model of ischemic stroke. J. Cereb. Blood Flow. Metab. 2020;40:S34-S48.
Not in our library10.1177/0271678x20932870
291.
Yang H, et al. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J. Exp. Med. 2015;212:5-14.
Not in our library10.1084/jem.20141318
292.
Kim EJ, et al. HMGB1 increases IL-1 beta production in vascular smooth muscle cells via NLRP3 inflammasome. Front. Physiol. 2018;9:313.
Not in our library10.3389/fphys.2018.00313
293.
Faraco G, et al. High mobility group box I protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J. Neurochem. 2007;103:590-603.
Not in our library10.1111/j.1471-4159.2007.04788.x
294.
Kim EK, Choi E-J. Compromised MAPK signaling in human diseases: an update. Arch. Toxicol. 2015;89:867-882.
Not in our library10.1007/s00204-015-1472-2
295.
Sun J, Nan G. The Mitogen-Activated Protein Kinase (MAPK) signaling pathway as a discovery target in stroke. J. Mol. Neurosci. 2016;59:90-98.
Not in our library10.1007/s12031-016-0717-8
296.
Choudhury GR, et al. Involvement of p38 MAPK in reactive astrogliosis induced by ischemic stroke. Brain Res. 2014;1551:45-58.
Not in our library10.1016/j.brainres.2014.01.013
297.
Zhang TS, et al. Excess salt intake promotes M1 microglia polarization via a p38/MAPK/AR-dependent pathway after cerebral ischemia in mice. Int. Immunopharmacol. 2020;81:106176.
Not in our library10.1016/j.intimp.2019.106176
298.
Cerebral ischemia induces micro vascular pro-inflammatory cytokine expression via the MEK/ERK pathway · 2010
No notice
299.
Zhang TS, et al. Excess salt exacerbates blood-brain barrier disruption via a p38/MAPK/SGK1-dependent pathway in permanent cerebral ischemia. Sci. Rep. 2015;5:16548.
Not in our library10.1038/srep16548
300.
Rosenberg GA, Yang Y. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg. Focus. 2007;22:E4-E4.
Not in our library10.3171/foc.2007.22.5.5
301.
Pfefferkorn T, Rosenberg GA. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke. 2003;34:2025-2030.
Not in our library10.1161/01.str.0000083051.93319.28
302.
Bao Dang Q, et al. High-density lipoproteins limit neutrophil-induced damage to the blood-brain barrier in vitro. J. Cereb. Blood Flow. Metab. 2013;33:575-582.
Not in our library10.1038/jcbfm.2012.206
303.
Barr TL, et al. Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke. 2010;41:E123-E128.
Not in our library10.1161/strokeaha.109.570515
304.
Zhu SZ, et al. Hypothermia followed by rapid rewarming exacerbates ischemia-induced brain injury and augments inflammatory response in rats. Biochem. Biophys. Res. Commun. 2016;474:175-181.
Not in our library10.1016/j.bbrc.2016.04.095
305.
Chelluboina B, et al. Matrix metalloproteinase-12 induces blood-brain barrier damage after focal cerebral ischemia. Stroke. 2015;46:3523-3531.
Not in our library10.1161/strokeaha.115.011031
306.
Chi OZ, et al. Hypoxic preconditioning increases blood-brain barrier disruption in the early stages of cerebral ischemia. Curr. Neurovasc. Res. 2017;14:26-31.
Not in our library10.2174/1567202614666161104114821
307.
Inhibition of HIF-1α Reduced Blood Brain Barrier Damage by Regulating MMP-2 and VEGF During Acute Cerebral Ischemia · 2018
Not checked
308.
Spiegel S, Milstien S. Sphingosine-1-phosphate: An enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. 2003;4:397-407.
Not in our library10.1038/nrm1103
309.
Lv M, et al. Sphingosine kinase 1/sphingosine-1-phosphate regulates the expression of interleukin-17A in activated microglia in cerebral ischemia/reperfusion. Inflamm. Res. 2016;65:551-562.
Not in our library10.1007/s00011-016-0939-9
310.
Hyakkoku K, et al. Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective effects against focal cerebral ischemia. Neuroscience. 2010;171:258-267.
Not in our library10.1016/j.neuroscience.2010.08.054
311.
Qin C, et al. Fingolimod protects against ischemic white matter damage by modulating microglia toward M2 polarization via STAT3 pathway. Stroke. 2017;48:3336-3346.
Not in our library10.1161/strokeaha.117.018505
312.
Schroder K, Tschopp J. The Inflammasomes. Cell. 2010;140:821-832.
Not in our library10.1016/j.cell.2010.01.040
313.
Mohamed IN, Ishrat T, Fagan SC, El-Remessy AB. Role of inflammasome activation in the pathophysiology of vascular diseases of the neurovascular unit. Antioxid. Redox Signal. 2015;22:1188-1206.
Not in our library10.1089/ars.2014.6126
314.
Fann DY-W, et al. Pathogenesis of acute stroke and the role of inflammasomes. Ageing Res. Rev. 2013;12:941-966.
Not in our library10.1016/j.arr.2013.09.004
315.
Yang F, et al. NLRP3 deficiency ameliorates neurovascular damage in experimental ischemic stroke. J. Cereb. Blood Flow. Metab. 2014;34:660-667.
Not in our library10.1038/jcbfm.2013.242
316.
HMGB1 promotes the activation of NLRP3 and caspase-8 inflammasomes via NF-κB pathway in acute glaucoma · 2015
No notice
317.
Fann DYW, et al. Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis. 2013;4:e790.
Not in our library10.1038/cddis.2013.326
318.
Wang K, et al. Central nervous system diseases related to pathological microglial phagocytosis. CNS Neurosci. Ther. 2021;27:528-539.
Not in our library10.1111/cns.13619
319.
Kawabori M, et al. Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) deficiency attenuates phagocytic activities of microglia and exacerbates ischemic damage in experimental stroke. J. Neurosci. 2015;35:3384-3396.
Not in our library10.1523/jneurosci.2620-14.2015
320.
Ting S-M, et al. Brain cleanup as a potential target for poststroke recovery the role of RXR (Retinoic X Receptor) in phagocytes. Stroke. 2020;51:958-966.
Not in our library10.1161/strokeaha.119.027315
321.
Brown GC, Neher JJ. Microglial phagocytosis of live neurons. Nat. Rev. Neurosci. 2014;15:209-216.
Not in our library10.1038/nrn3710
322.
Neher JJ, et al. Phagocytosis executes delayed neuronal death after focal brain ischemia. Proc. Natl Acad. Sci. USA. 2013;110:E4098-E4107.
Not in our library10.1073/pnas.1308679110
323.
TMEM16F Aggravates Neuronal Loss by Mediating Microglial Phagocytosis of Neurons in a Rat Experimental Cerebral Ischemia and Reperfusion Model · 2020
Not checked
324.
Gervois P, Lambrichts I. The emerging role of triggering receptor expressed on myeloid Cells 2 as a target for immunomodulation in ischemic stroke. Front. Immunol. 2019;10:1668.
Not in our library10.3389/fimmu.2019.01668
325.
Campagne MVL, Wiesmann C, Brown EJ. Macrophage complement receptors and pathogen clearance. Cell. Microbiol. 2007;9:2095-2102.
Not in our library10.1111/j.1462-5822.2007.00981.x
326.
Ma Y, Liu Y, Zhang Z, Yang G-Y. Significance of complement system in ischemic stroke: a comprehensive review. Aging Dis. 2019;10:429-462.
Not in our library10.14336/ad.2019.0119
327.
Fraser DA, Pisalyaput K, Tenner AJ. C1q enhances microglial clearance of apoptotic neurons and neuronal blebs, and modulates subsequent inflammatory cytokine production. J. Neurochem. 2010;112:733-743.
Not in our library10.1111/j.1471-4159.2009.06494.x
328.
Alawieh A, Langley EF, Tomlinson S. Targeted complement inhibition salvages stressed neurons and inhibits neuroinflammation after stroke in mice. Sci. Transl. Med. 2018;10:eaao6459.
Not in our library10.1126/scitranslmed.aao6459
329.
Alawieh AM, et al. Complement-dependent synaptic uptake and cognitive decline after stroke and reperfusion therapy. J. Neurosci. 2020;40:4042-4058.
Not in our library10.1523/jneurosci.2462-19.2020
330.
Fukuta T, et al. Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke. FASEB J. 2017;31:1879-1890.
Not in our library10.1096/fj.201601209r
331.
Rink C, Khanna S. MicroRNA in ischemic stroke etiology and pathology. Physiol. Genomics. 2011;43:521-528.
Not in our library10.1152/physiolgenomics.00158.2010
332.
Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell. Stem Cell. 2015;17:11-22.
Not in our library10.1016/j.stem.2015.06.007
333.
Chen Y, et al. Tat-NR2B9c prevents excitotoxic neuronal superoxide production. J. Cereb. Blood Flow. Metab. 2015;35:739-742.
Not in our library10.1038/jcbfm.2015.16
334.
Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012;483:213-U112.
Not in our library10.1038/nature10841
335.
Teves LM, Cui H, Tymianski M. Efficacy of the PSD95 inhibitor Tat-NR2B9c in mice requires dose translation between species. J. Cereb. Blood Flow. Metab. 2016;36:555-561.
Not in our library10.1177/0271678x15612099
336.
Soriano FX, et al. Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ Ligand. J. Neurosci. 2008;28:10696-10710.
Not in our library10.1523/jneurosci.1207-08.2008
337.
Hill MD, et al. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012;11:942-950.
Not in our library10.1016/s1474-4422(12)70225-9
338.
Luo C-X, et al. Interaction of nNOS with PSD-95 negatively controls regenerative repair after stroke. J. Neurosci. 2014;34:13535-13548.
Not in our library10.1523/jneurosci.1305-14.2014
339.
Hong JM, et al. Safety and optimal neuroprotection of neu2000 in acute Ischemic stroke with reCanalization: study protocol for a randomized, double-blinded, placebo-controlled, phase-II trial. Trials. 2018;19:375.
Not in our library10.1186/s13063-018-2746-9
340.
Cho SI, Park UJ, Chung J-M, Gwag BJ. NEU2000, AN NR2B-Selective, moderate nmda receptor antagonist and potent spin trapping molecule for stroke. Drug N. Perspect. 2010;23:549-556.
Not in our library10.1358/dnp.2010.23.9.1513493
341.
Ginsberg MD. Neuroprotection for ischemic stroke: Past, present and future. Neuropharmacology. 2008;55:363-389.
Not in our library10.1016/j.neuropharm.2007.12.007
342.
Takaoka S, et al. Neuroprotective effect of NMDA receptor glycine recognition site antagonism persists when brain temperature is controlled. J. Cereb. Blood Flow. Metab. 1997;17:161-167.
Not in our library10.1097/00004647-199702000-00005
343.
Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 1995;26:503-513.
Not in our library10.1161/01.str.26.3.503
344.
Lai TW, Shyu W-C, Wang YT. Stroke intervention pathways: NMDA receptors and beyond. Trends Mol. Med. 2011;17:266-275.
Not in our library10.1016/j.molmed.2010.12.008
345.
Wood PL, Hawkinson JE. N-methyl-D-aspartate antagonists for stroke and head trauma. Expert Opin. Investig. Drugs. 1997;6:389-397.
Not in our library10.1517/13543784.6.4.389
346.
Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke. 1995;26:254-258.
Not in our library10.1161/01.str.26.2.254
347.
Grotta J, et al. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke: Results of a phase IIa randomized trial. Stroke. 1995;26:602-605.
Not in our library10.1161/01.str.26.4.602
348.
Diener HC, et al. Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR - A safety and tolerability study. J. Neurol. 2002;249:561-568.
Not in our library10.1007/s004150200065
349.
Pei L, et al. DAPK1-p53 interaction converges necrotic and apoptotic pathways of ischemic neuronal death. J. Neurosci. 2014;34:6546-6556.
Not in our library10.1523/jneurosci.5119-13.2014
350.
Wang X, et al. Intervention of death-associated protein Kinase 1-p53 interaction exerts the therapeutic effects against stroke. Stroke. 2014;45:3089.
Not in our library10.1161/strokeaha.114.006348
351.
McQueen J, et al. Pro-death NMDA receptor signaling is promoted by the GIuN2B C-terminus independently of Dapk1. Elife. 2017;6:e17161.
Not in our library10.7554/elife.17161
352.
Huang BS, et al. Geniposide attenuates post-ischaemic neurovascular damage via GluN2A/AKT/ERK-dependent mechanism. Cell. Physiol. Biochem. 2017;43:705-716.
Not in our library10.1159/000480657
353.
Liu Y, et al. Neuroprotective effect of pseudoginsenoside-F11 on permanent cerebral ischemia in rats by regulating calpain activity and NR2A submit-mediated AKT-CREB signaling pathways. Phytomed: Int. J. Phytother. Phytopharmacol. 1800;96:153847.
Not in our library10.1016/j.phymed.2021.153847
354.
Alim I, et al. Modulation of NMDAR subunit expression by TRPM2 channels regulates neuronal vulnerability to ischemic cell death. J. Neurosci. 2013;33:17264-17277.
Not in our library10.1523/jneurosci.1729-13.2013
355.
Thompson RJ. Pannexin channels and ischaemia. J. Physiol. -Lond. 2015;593:3463-3470.
Not in our library10.1113/jphysiol.2014.282426
356.
Weilinger NL, et al. Metabotropic NMDA receptor signaling couples Src family kinases to pannexin-1 during excitotoxicity. Nat. Neurosci. 2016;19:432.
Not in our library10.1038/nn.4236
357.
Alfieri A, et al. Sulforaphane preconditioning of the Nrf2/HO-1 defense pathway protects the cerebral vasculature against blood-brain barrier disruption and neurological deficits in stroke. Free Radic. Biol. Med. 2013;65:1012-1022.
Not in our library10.1016/j.freeradbiomed.2013.08.190
358.
Hou Y, et al. Nrf2 inhibits NLRP3 inflammasome activation through regulating Trx1/TXNIP complex in cerebral ischemia reperfusion injury. Behav. Brain Res. 2018;336:32-39.
Not in our library10.1016/j.bbr.2017.06.027
359.
Role of Nrf2 and protective effects of Metformin against tobacco smoke-induced cerebrovascular toxicity · 2017
Not checked
360.
Zhang W, et al. Sirtuin 6 Protects the brain from cerebral ischemia/reperfusion injury through NRF2 activation. Neuroscience. 2017;366:95-104.
Not in our library10.1016/j.neuroscience.2017.09.035
361.
Hou J, Chong ZZ, Shang YC, Maiese K. Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation. Curr. Neurovasc. Res. 2010;7:95-112.
Not in our library10.2174/156720210791184899
362.
Morris KC, Lin HW, Thompson JW, Perez-Pinzon MA. Pathways for ischemic cytoprotection: Role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning. J. Cereb. Blood Flow. Metab. 2011;31:1003-1019.
Not in our library10.1038/jcbfm.2010.229
363.
Wang R, et al. Curcumin attenuates IR-induced myocardial injury by activating SIRT3. Eur. Rev. Med. Pharmacol. Sci. 2018;22:1150-1160.
Not in our library10.26355/eurrev_201802_14404
364.
Chang G, Chen Y, Zhang H, Zhou W. Trans sodium crocetinate alleviates ischemia/reperfusion-induced myocardial oxidative stress and apoptosis via the SIRT3/FOXO3a/SOD2 signaling pathway. Int. Immunopharmacol. 2019;71:361-371.
Not in our library10.1016/j.intimp.2019.03.056
365.
Zhao B, et al. Genipin protects against cerebral ischemia-reperfusion injury by regulating the UCP2-SIRT3 signaling pathway. Eur. J. Pharmacol. 2019;845:56-64.
Not in our library10.1016/j.ejphar.2018.12.028
366.
Hammond MD, et al. CCR2(+)Ly6C(hi) inflammatory monocyte recruitment exacerbates acute disability following intracerebral hemorrhage. J. Neurosci. 2014;34:3901-3909.
Not in our library10.1523/jneurosci.4070-13.2014
367.
Wattananit S, et al. Monocyte-derived macrophages contribute to spontaneous long-term functional recovery after stroke in mice. J. Neurosci. 2016;36:4182-4195.
Not in our library10.1523/jneurosci.4317-15.2016
368.
Lu Y-Y, Ma X-J, Yang Y-N. MicroRNA-18a-5p mitigates oxygen-glucose-deprivation/reoxygenation-induced injury through suppression of TLRs/NF-kappa B signaling by targeting TLR8 in PC12 cells. Biosci., Biotechnol. Biochem. 2020;84:2476-2483.
Not in our library10.1080/09168451.2020.1806705
369.
Ghazavi H, et al. The role of resveratrol as a natural modulator in glia activation in experimental models of stroke. Avicenna J. Phytomed. 2020;10:557-573.
Not in our library
370.
Rahimifard M, et al. Targeting the TLR4 signaling pathway by polyphenols: A novel therapeutic strategy for neuroinflammation. Ageing Res. Rev. 2017;36:11-19.
Not in our library10.1016/j.arr.2017.02.004
371.
Zhang X-S, et al. Resveratrol attenuates acute inflammatory injury in experimental subarachnoid hemorrhage in rats via inhibition of TLR4 pathway. Int. J. Mol. Sci. 2016;17:1331.
Not in our library10.3390/ijms17081331
372.
Zan J, et al. Isosteviol sodium injection improves outcomes by modulating TLRs/NF-B-dependent inflammatory responses following experimental traumatic brain injury in rats. Neuroreport. 2018;29:794-803.
Not in our library10.1097/wnr.0000000000001033
373.
Hsieh JT, et al. Sex-specific effects of progesterone on early outcome of intracerebral hemorrhage. Neuroendocrinology. 2016;103:518-530.
Not in our library10.1159/000440883
374.
Li X, et al. Progesterone reduces inflammation and apoptosis in neonatal rats with hypoxic ischemic brain damage through the PI3K/Akt pathway. Int. J. Clin. Exp. Med. 2015;8:8197-8203.
Not in our library
375.
Wang Z, et al. Progesterone administration modulates cortical TLR4/NF-kappa B signaling pathway after subarachnoid hemorrhage in male rats. Mediators Inflamm. 2011;2011:848309.
Not in our library10.1155/2011/848309
376.
Zhai Y, et al. Dexmedetomidine post-conditioning alleviates cerebral ischemia-reperfusion injury in rats by inhibiting high mobility group Protein B1 Group (HMGB1)/Toll-Like Receptor 4 (TLR4)/Nuclear Factor kappa B (NF-kappa B) Signaling Pathway. Med. Sci. Monit. 2020;26:e918617.
Not in our library10.12659/msm.918617
377.
Leung PY, et al. Toll-like Receptor 7 preconditioning induces robust neuroprotection against stroke by a novel Type I interferon-mediated mechanism. Stroke. 2012;43:1383-1389.
Not in our library10.1161/strokeaha.111.641522
378.
Clausen BH, et al. Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia. J. Neuroinflammation. 2014;11:203.
Not in our library10.1186/s12974-014-0203-6
379.
Zhou Q-H, et al. Brain-penetrating tumor necrosis factor decoy receptor in the mouse. Drug Metab. Disposition. 2011;39:71-76.
Not in our library10.1124/dmd.110.036012
380.
Sumbria RK, Boado RJ, Pardridge WM. Brain protection from stroke with intravenous TNF alpha decoy receptor-Trojan horse fusion protein. J. Cereb. Blood Flow. Metab. 2012;32:1933-1938.
Not in our library10.1038/jcbfm.2012.97
381.
Liguz-Lecznar M, Zakrzewska R, Kossut M. Inhibition of Tnf-alpha R1 signaling can rescue functional cortical plasticity impaired in early post-stroke period. Neurobiol. Aging. 2015;36:2877-2884.
Not in our library10.1016/j.neurobiolaging.2015.06.015
382.
Works MG, Koenig JB, Sapolsky RM. Soluble TNF receptor 1-secreting ex vivo-derived dendritic cells reduce injury after stroke. J. Cereb. Blood Flow. Metab. 2013;33:1376-1385.
Not in our library10.1038/jcbfm.2013.100
383.
Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor-alpha blockers etanercept, infliximab, and adalimumab. J. Dermatol. Treat. 2004;15:280-294.
Not in our library10.1080/09546630410017275
384.
Relton JK, Martin D, Thompson RC, Russell DA. Peripheral administration of interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp. Neurol. 1996;138:206-213.
Not in our library10.1006/exnr.1996.0059
385.
Loddick SA, Rothwell NJ. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J. Cereb. Blood Flow. Metab. 1996;16:932-940.
Not in our library10.1097/00004647-199609000-00017
386.
Nawashiro H, Martin D, Hallenbeck JM. Neuroprotective effects of TNF binding protein in focal cerebral ischemia. Brain Res. 1997;778:265-271.
Not in our library10.1016/s0006-8993(97)00981-5
387.
Emsley HCA, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry. 2005;76:1366-1372.
Not in our library10.1136/jnnp.2004.054882
388.
Gueorguieva I, et al. Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. Br. J. Clin. Pharmacol. 2008;65:317-325.
Not in our library10.1111/j.1365-2125.2007.03026.x
389.
Granowitz EV, et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. 1992;4:353-360.
Not in our library10.1016/1043-4666(92)90078-6
390.
Smith CJ, et al. SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke) a randomized controlled Phase 2 Trial. Stroke. 2018;49:1210.
Not in our library10.1161/strokeaha.118.020750
391.
NLRP3 inflammasome as a potential treatment in ischemic stroke concomitant with diabetes · 2019
No notice
392.
Ye XC, et al. Purinergic 2X7 receptor/NLRP3 pathway triggers neuronal apoptosis after ischemic stroke in the mouse. Exp. Neurol. 2017;292:46-55.
Not in our library10.1016/j.expneurol.2017.03.002
393.
Wang, S. Q. et al. Genistein attenuates acute cerebral ischemic damage by inhibiting the NLRP3 inflammasome in reproductively senescent mice. Front. Aging Neurosci. 12, (2020).
Not in our library10.3389/fnagi.2020.00153
394.
Chen XY, Wang YZ, Yao NN, Lin ZJ. Immunoproteasome modulates NLRP3 inflammasome-mediated neuroinflammation under cerebral ischaemia and reperfusion conditions. J. Cell. Mol. Med. 2022;26:462-474.
Not in our library10.1111/jcmm.17104
395.
Yang R, et al. Quercetin attenuates ischemia reperfusion injury by protecting the blood-brain barrier through Sirt1 in MCAO rats. J. Asian Nat. Prod. Res. 2022;24:278-289.
Not in our library10.1080/10286020.2021.1949302
396.
Yang F, et al. Minocycline ameliorates hypoxia-induced blood-brain barrier damage by inhibition of HIF-1 alpha through sirt-3/PHD-2 degradation pathway. Neuroscience. 2015;304:250-259.
Not in our library10.1016/j.neuroscience.2015.07.051
397.
Liu H, et al. Hydrogen sulfide attenuates tissue plasminogen activator-induced cerebral hemorrhage following experimental stroke. Transl. Stroke Res. 2016;7:209-219.
Not in our library10.1007/s12975-016-0459-5
398.
Yang Y, et al. Non-invasive vagus nerve stimulation reduces blood-brain barrier disruption in a rat model of ischemic stroke. Brain Stimul. 2018;11:689-698.
Not in our library10.1016/j.brs.2018.01.034
399.
Michalski D, et al. Early outcome and blood-brain barrier integrity after co-administered thrombolysis and hyperbaric oxygenation in experimental stroke. Exp. Transl. Stroke Med. 2011;3:5-5.
Not in our library10.1186/2040-7378-3-5
400.
Khan IS, et al. Intraarterial administration of norcantharidin attenuates ischemic stroke damage in rodents when given at the time of reperfusion: novel uses of endovascular capabilities. J. Neurosurg. 2016;125:152-159.
Not in our library10.3171/2015.4.jns142400
401.
Hasegawa Y, et al. Activation of Sphingosine 1-Phosphate Receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke. 2010;41:368-374.
Not in our library10.1161/strokeaha.109.568899
402.
Wei Y, et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann. Neurol. 2011;69:119-129.
Not in our library10.1002/ana.22186
403.
Fingolimod suppresses neuronal autophagy through the mTOR/p70S6K pathway and alleviates ischemic brain damage in mice. · 2017
Not checked
404.
Yang, B. A. et al. Selenium attenuates ischemia/reperfusion injury-induced damage to the blood-brain barrier in hyperglycemia through PI3K/AKT/mTOR pathway-mediated autophagy inhibition. Int. J. Mol. Med. 48, (2021).
Not in our library10.3892/ijmm.2021.5011
405.
Guo Z, et al. A combination of four active compounds alleviates cerebral ischemia-reperfusion injury in correlation with inhibition of autophagy and modulation of AMPK/mTOR and JNK pathways. J. Neurosci. Res. 2014;92:1295-1306.
Not in our library10.1002/jnr.23400
406.
Wang, G. et al. Schizandrin protects against OGD/R-induced neuronal injury by suppressing autophagy: involvement of the AMPK/mTOR pathway. Molecules. 24, (2019).
Not in our library10.3390/molecules24193624
407.
Yu J, et al. Ezetimibe, a NPC1L1 inhibitor, attenuates neuronal apoptosis through AMPK dependent autophagy activation after MCAO in rats. Exp. Neurol. 2018;307:12-23.
Not in our library10.1016/j.expneurol.2018.05.022
408.
Schwalm C, et al. Activation of autophagy in human skeletal muscle is dependent on exercise intensity and AMPK activation. Faseb. J. 2015;29:3515-3526.
Not in our library10.1096/fj.14-267187
409.
Batatinha HAP, et al. Regulation of autophagy as a therapy for immunosenescence-driven cancer and neurodegenerative diseases: The role of exercise. J. Cell. Physiol. 2019;234:14883-14895.
Not in our library10.1002/jcp.28318
410.
Pan G, et al. Treadmill exercise improves neurological function by inhibiting autophagy and the binding of HMGB1 to Beclin1 in MCAO juvenile rats. Life Sci. 2020;243:117279.
Not in our library10.1016/j.lfs.2020.117279
411.
Small extracellular vesicles secreted by human iPSC-derived MSC enhance angiogenesis through inhibiting STAT3-dependent autophagy in ischemic stroke · 2020
No notice
412.
Mei Z-G, et al. Electroacupuncture ameliorates cerebral ischemia/reperfusion injury by suppressing autophagy via the SIRT1-FOXO1 signaling pathway. Aging-Us. 2020;12:13187-13205.
Not in our library10.18632/aging.103420
413.
Xu SY, et al. Electroacupuncture alleviates cerebral ischemia/reperfusion injury in rats by Histone H4 Lysine 16 acetylation-mediated autophagy. Front. Psychiatry. 2020;11:576539.
Not in our library10.3389/fpsyt.2020.576539
414.
Liu S, et al. Luteolin protects against CIRI, potentially via regulation of the SIRT3/AMPK/mTOR signaling pathway. Neurochem. Res. 2020;45:2499-2515.
Not in our library10.1007/s11064-020-03108-w
415.
Liu L, et al. Melatonin ameliorates cerebral ischemia-reperfusion injury in diabetic mice by enhancing autophagy via the SIRT1-BMAL1 pathway. FASEB J. 2021;35:e22040.
Not in our library10.1096/fj.202002718rr
416.
Li Y, Zhang XP, Ma AJ, Kang Y. Rational application of beta-Hydroxybutyrate attenuates ischemic stroke by suppressing oxidative stress and mitochondrial-dependent apoptosis via activation of the Erk/CREB/eNOS pathway. ACS Chem. Neurosci. 2021;12:1219-1227.
Not in our library10.1021/acschemneuro.1c00046
417.
Yong Y-X, et al. Up-regulated microRNA-199b-3p represses the apoptosis of cerebral microvascular endothelial cells in ischemic stroke through down-regulation of MAPK/ERK/EGR1 axis. Cell Cycle. 2019;18:1868-1881.
Not in our library10.1080/15384101.2019.1632133
418.
Xiong W, et al. DAPK1-ERK signal mediates oxygen glucose deprivation reperfusion induced apoptosis in mouse N2a cells. J. Neurol. Sci. 2018;387:210-219.
Not in our library10.1016/j.jns.2018.01.003
419.
Guo T, et al. Promoting role of long non-coding RNA small nucleolar RNA Host Gene 15 (SNHG15) in neuronal injury following ischemic stroke via the MicroRNA-18a/CXC Chemokine Ligand 13 (CXCL13)/ERK/MEK Axis. Med. Sci. Monit. 2020;26:e923610.
Not in our library10.12659/msm.923610
420.
Hu Y, et al. AMPK inhibitor BML-275 induces neuroprotection through decreasing cyt c and AIF expression after transient brain ischemia. Biorg. Med. Chem. 2021;52:116522.
Not in our library10.1016/j.bmc.2021.116522
421.
Chen ZJ, et al. Glycine improves ischemic stroke through miR-19a-3p/AMPK/GSK-3 beta/HO-1 pathway. Drug Des. Devel. Ther. 2020;14:2021-2031.
Not in our library10.2147/dddt.s248104
422.
Yan L, Zhu T. Effects of rosuvastatin on neuronal apoptosis in cerebral ischemic stroke rats via Sirt1/NF-kappa B signaling pathway. Eur. Rev. Med. Pharmacol. Sci. 2019;23:5449-5455.
Not in our library10.26355/eurrev_201906_18214
423.
Sarmah D, et al. Sirtuin-1 - Mediated NF-κB pathway modulation to mitigate inflammasome signaling and cellular apoptosis is one of the neuroprotective effects of intra-arterial mesenchymal stem cell therapy following ischemic stroke. Stem. Cell. Rev. Rep. 2022;18:821-838.
Not in our library10.1007/s12015-021-10315-7
424.
Xu J, Wang C, Meng F, Xu P. Long non-coding RNA H19 inhibition ameliorates oxygen-glucose deprivation-induced cell apoptosis and inflammatory cytokine expression by regulating the microRNA-29b/SIRT1/PGC-1 alpha axis. Mol. Med. Rep. 2021;23:131.
Not in our library10.3892/mmr.2020.11770
425.
Clinical Trials of Stem Cell Therapy for Cerebral Ischemic Stroke · 2020
No notice
426.
Zhou L, et al. Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nat. Med. 2010;16:1439-1443.
Not in our library10.1038/nm.2245
427.
Bach A, et al. Biochemical investigations of the mechanism of action of small molecules ZL006 and IC87201 as potential inhibitors of the nNOS-PDZ/PSD-95-PDZ interactions. Sci. Rep. 2015;5:12157.
Not in our library10.1038/srep12157
428.
Kim YR, et al. Electroacupuncture confers beneficial effects through ionotropic glutamate receptors involving phosphatidylinositol-3 kinase/Akt signaling pathway in focal cerebral ischemia in rats. Eur. J. Int. Med. 2012;4:E413-E420.
Not in our library10.1016/j.eujim.2012.06.004
429.
Weilinger NL, Tang PL, Thompson RJ. Anoxia-induced NMDA receptor activation opens pannexin channels via Src Family Kinases. J. Neurosci. 2012;32:12579-12588.
Not in our library10.1523/jneurosci.1267-12.2012
430.
Abdul Y, et al. Inhibition of Toll-Like Receptor-4 (TLR-4) improves neurobehavioral outcomes after acute ischemic stroke in diabetic rats: possible role of vascular endothelial TLR-4. Mol. Neurobiol. 2019;56:1607-1617.
Not in our library10.1007/s12035-018-1184-8
431.
Shi H, et al. Role of Toll-like receptor-mediated signaling in traumatic brain injury. Neuropharmacology. 2019;145:259-267.
Not in our library10.1016/j.neuropharm.2018.07.022
432.
TLR2 and TLR4 in the Brain Injury Caused by Cerebral Ischemia and Reperfusion · 2013
No notice
433.
Gui B, et al. Neuroprotective effects of pretreatment with Propofol in LPS-induced BV-2 microglia cells: role of TLR4 and GSK-3 beta. Inflammation. 2012;35:1632-1640.
Not in our library10.1007/s10753-012-9478-x
434.
Marik PE. Propofol: An immunomodulating agent. Pharmacotherapy. 2005;25:28S-33S.
Not in our library10.1592/phco.2005.25.5_part_2.28s
435.
Yang R, et al. Quercetin attenuates ischemia reperfusion injury by protecting the blood-brain barrier through Sirt1 in MCAO rats. J. Asian Nat. Prod. Res. 2021;24:278-289.
Not in our library10.1080/10286020.2021.1949302
436.
Wei LL, et al. Patchouli alcohol protects against ischemia/reperfusion-induced brain injury via inhibiting neuroinflammation in normal and obese mice. Brain Res. 2018;1682:61-70.
Not in our library10.1016/j.brainres.2017.12.039
437.
Mamtilahun M, et al. DL-3n-Butylphthalide improves blood-brain barrier integrity in rat after middle cerebral artery occlusion. Front. Cell. Neurosci. 2021;14:610714.
Not in our library10.3389/fncel.2020.610714
438.
Qi ZF, et al. AKT-related autophagy contributes to the neuroprotective efficacy of Hydroxysafflor Yellow A against ischemic stroke in rats. Transl. Stroke Res. 2014;5:501-509.
Not in our library10.1007/s12975-014-0346-x
439.
Wang MM, et al. Electroacupuncture inhibits neuronal autophagy and apoptosis via the PI3K/AKT pathway following ischemic stroke. Front. Cell. Neurosci. 2020;14:134.
Not in our library10.3389/fncel.2020.00134
440.
Meng J, Ma H, Zhu Y, Zhao Q. Dehydrocostuslactone attenuated oxygen and glucose deprivation/reperfusion-induced PC12 cell injury through inhibition of apoptosis and autophagy by activating the PI3K/AKT/mTOR pathway. Eur. J. Pharmacol. 2021;911:174554.
Not in our library10.1016/j.ejphar.2021.174554
441.
Zhang X, et al. Alterations of brain quantitative proteomics profiling revealed the molecular mechanisms of diosgenin against cerebral lschemia reperfusion effects. J. Proteome Res. 2020;19:1154-1168.
Not in our library10.1021/acs.jproteome.9b00667
442.
Yang B, et al. Melatonin plays a protective role by regulating miR-26a-5p-NRSF and JAK2-STAT3 pathway to improve autophagy, inflammation and oxidative stress of cerebral ischemia-reperfusion injury. Drug Des. Dev. Ther. 2020;14:3177-3188.
Not in our library10.2147/dddt.s262121
443.
Pan Q, et al. MTMR14 protects against cerebral stroke through suppressing PTEN-regulated autophagy. Biochem. Biophy. Res. Commun. 2020;529:1045-1052.
Not in our library10.1016/j.bbrc.2020.06.096
444.
Xue H, et al. Sevoflurane post-conditioning alleviates neonatal rat hypoxic-ischemic cerebral injury via Ezh2-regulated autophagy. Drug Des. Dev. Ther. 2019;13:1691-1706.
Not in our library10.2147/dddt.s197325
445.
Zhong S-J, et al. MicroRNA-144 promotes remote limb ischemic preconditioning-mediated neuroprotection against ischemic stroke via PTEN/Akt pathway. Acta Neurol. Belg. 2021;121:95-106.
Not in our library10.1007/s13760-020-01500-5
446.
Mu Q, et al. NPD1 inhibits excessive autophagy by targeting RNF146 and wnt/beta-catenin pathway in cerebral ischemia-reperfusion injury. J. Recept. Signal Transduct. 2020;40:456-463.
Not in our library10.1080/10799893.2020.1756325
447.
Chen C, et al. Electroacupuncture pretreatment prevents ischemic stroke and inhibits Wnt signaling-mediated autophagy through the regulation of GSK-3 beta phosphorylation. Brain Res. Bull. 2020;158:90-98.
Not in our library10.1016/j.brainresbull.2020.03.002
448.
He H, et al. Puerarin provides a neuroprotection against transient cerebral ischemia by attenuating autophagy at the ischemic penumbra in neurons but not in astrocytes. Neurosci. Lett. 2017;643:45-51.
Not in our library10.1016/j.neulet.2017.02.031
449.
Fu K, et al. Grape seed proanthocyanidins attenuate apoptosis in ischemic stroke. Acta Neurol. Belg. 2021;121:357-364.
Not in our library10.1007/s13760-019-01111-9
450.
Yang Y, et al. Apelin-13 protects against apoptosis by activating AMP-activated protein kinase pathway in ischemia stroke. Peptides. 2016;75:96-100.
Not in our library10.1016/j.peptides.2015.11.002
451.
Gao JF, Qian TT, Wang W. CTRP3 Activates the AMPK/SIRT1-PGC-1 alpha pathway to protect mitochondrial biogenesis and functions in cerebral ischemic stroke. Neurochem. Res. 2020;45:3045-3058.
Not in our library10.1007/s11064-020-03152-6
452.
Lv H, et al. Salvianolic acid B attenuates apoptosis and inflammation via SIRT1 activation in experimental stroke rats. Brain Res. Bull. 2015;115:30-36.
Not in our library10.1016/j.brainresbull.2015.05.002
453.
Sarmah D, et al. Sirtuin-1-mediated NF-kappa B pathway modulation to mitigate inflammasome signaling and cellular apoptosis is one of the neuroprotective effects of intra-arterial mesenchymal stem cell therapy following ischemic stroke. Stem. Cell. Rev. Rep. 2022;18:821-838.
Not in our library10.1007/s12015-021-10315-7
454.
Zhou M, et al. A DNA nanostructure-based neuroprotectant against neuronal apoptosis via inhibiting toll-like Receptor 2 signaling pathway in acute ischemic stroke. ACS Nano. 2022;16:1456-1470.
Not in our library10.1021/acsnano.1c09626
455.
Gu J, et al. Anti-inflammatory and anti-apoptotic effects of the combination of Ligusticum chuanxiong and Radix Paeoniae against focal cerebral ischaemia via TLR4/MyD88/MAPK/NF-kappa B signalling pathway in MCAO rats. J. Pharm. Pharmacol. 2018;70:268-277.
Not in our library10.1111/jphp.12841

Cited by papers we hold 1

Review: Enhancing the Bioavailability and Stability of Anthocyanins for the Prevention and Treatment of Central Nervous System-Related Diseases · 2025
Not checked

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.